<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6152054</article-id><article-id pub-id-type="doi">10.3390/molecules22081290</article-id><article-id pub-id-type="publisher-id">molecules-22-01290</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Essential Oils and Their Constituents: An Alternative Source for Novel Antidepressants</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7180-4896</contrib-id><name><surname>de Sousa</surname><given-names>Dami&#x000e3;o P.</given-names></name><xref ref-type="aff" rid="af1-molecules-22-01290">1</xref></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Rayanne H. N.</given-names></name><xref ref-type="aff" rid="af1-molecules-22-01290">1</xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Epifanio F.</given-names></name><xref ref-type="aff" rid="af2-molecules-22-01290">2</xref></contrib><contrib contrib-type="author"><name><surname>Gavioli</surname><given-names>Elaine C.</given-names></name><xref ref-type="aff" rid="af2-molecules-22-01290">2</xref><xref rid="c1-molecules-22-01290" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-molecules-22-01290"><label>1</label>Departamento de Ci&#x000ea;ncias Farmac&#x000ea;uticas, Universidade Federal da Para&#x000ed;ba, Jo&#x000e3;o Pessoa, PB 58051-970, Brazil; <email>damiao_desousa@yahoo.com.br</email> (D.P.d.S.); <email>rayanne_nasci@hotmail.com</email> (R.H.N.S.)</aff><aff id="af2-molecules-22-01290"><label>2</label>Departamento de Biof&#x000ed;sica e Farmacologia, Universidade Federal do Rio Grande do Norte, Natal, RN 59078-970, Brazil; <email>epifaniofsilva@hotmail.com</email></aff><author-notes><corresp id="c1-molecules-22-01290"><label>*</label>Correspondence: <email>egavioli@hotmail.com</email>; Tel.: +55-84-3215-3419</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2017</year></pub-date><volume>22</volume><issue>8</issue><elocation-id>1290</elocation-id><history><date date-type="received"><day>06</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Depression is a disease that has affected a high proportion of the world&#x02019;s population and people of different ages, incapacitating them from good performance at work and in social relationships, and causing emotional disorders to millions of families. Therefore, the search for new therapeutic agents is considered a priority for the discovery of more effective forms of treatment. In this review, studies of essential oils and their constituents in experimental models related to depression are discussed. The mechanisms of action of the oils and the presence of psychoactive constituents in their chemical compositions are discussed. The data in the review show the therapeutic potential of essential oils and their chemical constituents for use in depressive disorders. Advanced studies using humans are needed to confirm the antidepressant properties described in animals.</p></abstract><kwd-group><kwd>oil</kwd><kwd>terpene</kwd><kwd>natural products</kwd><kwd>major depression</kwd><kwd>antidepressant</kwd><kwd>animal models</kwd></kwd-group></article-meta></front><body><sec id="sec1-molecules-22-01290"><title>1. Introduction</title><p>Depression is one of the most prevalent and costly psychiatric disorders; it leads to substantial cognitive and affective disturbances, and negatively impacts the overall quality of life. Major depression is manifested through psychological, behavioral and physiological symptoms, comprised of depressed mood, markedly diminished pleasure in most activities, loss of energy, poor concentration, alterations in appetite and sleeping patterns, feelings of worthlessness, excessive guilt, and thoughts of death or suicide [<xref rid="B1-molecules-22-01290" ref-type="bibr">1</xref>]. A systematic review has predicted an average prevalence for major depression at a global level of 4.7% [<xref rid="B2-molecules-22-01290" ref-type="bibr">2</xref>]. This means that one out of every 20 people in the world is affected by depression. The prevalence estimated for depression in women was 5.9% and 3.8% for men [<xref rid="B2-molecules-22-01290" ref-type="bibr">2</xref>]. Women are thus almost twice as likely to suffer from major depression as men.</p></sec><sec id="sec2-molecules-22-01290"><title>2. Pharmacological Management of Major Depression</title><p>Conventional antidepressant drugs ultimately act by increasing monoamine levels at the synaptic cleft by either: (i) blocking presynaptic monoamine transporter proteins, which remove released transmitters from the extracellular space; (ii) inhibiting the enzyme monoamine oxidase, which degrades monoamine neurotransmitters; or (iii) interacting with pre- or postsynaptic receptors that regulate monoamine transmitter release and/or neuronal firing rate [<xref rid="B3-molecules-22-01290" ref-type="bibr">3</xref>]. It has been proposed that as antidepressant drugs increase extracellular monoamine concentrations, depression might be produced by deficiencies in noradrenaline, 5-HT and dopamine at their receptor sites in the brain. This proposal is known as the monoamine depression hypothesis [<xref rid="B4-molecules-22-01290" ref-type="bibr">4</xref>]. Although the effects of antidepressants on monoamines can be seen soon after administration, it generally takes a few weeks of continued treatment for therapeutic responses to appear. Due to the therapeutic delay of antidepressants, problems involving the neural network&#x02019;s processing of information, rather than chemical disequilibrium, might well underlie depression [<xref rid="B4-molecules-22-01290" ref-type="bibr">4</xref>]. In fact, conventional antidepressants mediate their effects by increasing Brain-Derived Neurotropic Factor (BDNF) in the forebrain regions, particularly in the hippocampus, making BDNF an essential determinant of antidepressant efficacy. BDNF acts in the brain inducing neuroplasticity, which results in depressive symptom improvements [<xref rid="B5-molecules-22-01290" ref-type="bibr">5</xref>], and it has already been shown that hippocampal neurogenesis is a requirement for the therapeutic effects of antidepressants [<xref rid="B6-molecules-22-01290" ref-type="bibr">6</xref>].</p><p>Depression pharmacotherapy is costly, though widely prescribed by physicians. However, less than half of the patients treated obtain complete remission through therapy with single antidepressant drugs. Some patients exhibit partial or no remission and some patients display treatment intolerance responses. This emphasizes the need to identify novel classes of antidepressants [<xref rid="B7-molecules-22-01290" ref-type="bibr">7</xref>]. The most frequent side effects of these drugs are due to rapid monoamine concentration increases at the receptor sites. These effects could be summarized as increased anxiety, gastrointestinal and sexual problems and decreased alertness. The challenge for such new antidepressants is to achieve fast antidepressant response, broader efficacy, and fewer adverse effects [<xref rid="B7-molecules-22-01290" ref-type="bibr">7</xref>].</p><p>Being a rich source for bioactive molecules, medicinal plants provide hope for development of novel antidepressant drugs [<xref rid="B8-molecules-22-01290" ref-type="bibr">8</xref>,<xref rid="B9-molecules-22-01290" ref-type="bibr">9</xref>,<xref rid="B10-molecules-22-01290" ref-type="bibr">10</xref>]. An alternative approach might come from aromatic plants. Although certain essential oils found in plants have been used as traditional medicines, little scientific evidence supports their use. Essential oils are complex mixtures of volatile compounds produced by aromatic plants [<xref rid="B11-molecules-22-01290" ref-type="bibr">11</xref>]. Recent clinical studies show that essential oils, inhaled or orally administered, enter the blood stream and exert psychological effects, thus complementing pharmacodynamic mediation. For instance, inhalation, or oral administration of essential oils improves the quality of sleep [<xref rid="B12-molecules-22-01290" ref-type="bibr">12</xref>,<xref rid="B13-molecules-22-01290" ref-type="bibr">13</xref>], attenuates symptoms of dementia [<xref rid="B14-molecules-22-01290" ref-type="bibr">14</xref>,<xref rid="B15-molecules-22-01290" ref-type="bibr">15</xref>], negative affect [<xref rid="B16-molecules-22-01290" ref-type="bibr">16</xref>], anxiety [<xref rid="B11-molecules-22-01290" ref-type="bibr">11</xref>,<xref rid="B17-molecules-22-01290" ref-type="bibr">17</xref>], nicotine craving [<xref rid="B18-molecules-22-01290" ref-type="bibr">18</xref>], post-traumatic stress disorder [<xref rid="B19-molecules-22-01290" ref-type="bibr">19</xref>] and Alzheimer&#x02019;s disease [<xref rid="B20-molecules-22-01290" ref-type="bibr">20</xref>]. Preclinical pharmacological studies of essential oils and/or their isolated chemical constituents are becoming more common [<xref rid="B21-molecules-22-01290" ref-type="bibr">21</xref>,<xref rid="B22-molecules-22-01290" ref-type="bibr">22</xref>,<xref rid="B23-molecules-22-01290" ref-type="bibr">23</xref>,<xref rid="B24-molecules-22-01290" ref-type="bibr">24</xref>]. In fact, several studies have shown that the aromatherapy could to be used as a complementary and alternative therapy for patients with depression and secondary depressive symptoms [<xref rid="B25-molecules-22-01290" ref-type="bibr">25</xref>], including anxiety disorders [<xref rid="B26-molecules-22-01290" ref-type="bibr">26</xref>]. In a review published on plants used in aromatherapy for anxiety treatment, the contributions of the chemical constituents of their essential oils in this therapeutic effect are discussed [<xref rid="B27-molecules-22-01290" ref-type="bibr">27</xref>], while a recent systematic review discusses the anxiolytic action of essential oils and their constituents [<xref rid="B11-molecules-22-01290" ref-type="bibr">11</xref>]. The objective for this review is to discuss certain essential oils and their isolated constituents being tested in humans and rodents for treatment of major depression. These essential oils and their constituents have been pre-clinically tested for their antidepressant activity and are, respectively, illustrated in <xref rid="molecules-22-01290-t001" ref-type="table">Table 1</xref> and <xref rid="molecules-22-01290-t002" ref-type="table">Table 2</xref>. In addition, the proposed mechanisms by which essential oils and their isolated compounds produce antidepressant actions are also discussed. Considering all of the information herewith presented, essential oils might well be an alternative source of therapy for the relief of major depression symptoms.</p></sec><sec id="sec3-molecules-22-01290"><title>3. Methodology</title><p>The present study was carried out based on the literature review of plants and their essential oils with antidepressant activity. Chemical structure and name of bioactive compounds, as well as references are also provided. All species mentioned in the text were validated taxonomically on Database (<uri xlink:href="www.theplantlist.orgW3Tropicos">www.theplantlist.orgW3Tropicos</uri>).</p><p>The plant species presented here were selected based on the effects shown by their essential oils in specific animal models used for evaluation of antidepressant activity and/or by complementary studies, aimed at elucidating the mechanism(s) of action of the oils or individual components. To select the essential oil constituents, terms related to the theme, such as &#x0201c;essential oils&#x0201d;, &#x0201c;monoterpenes&#x0201d; and &#x0201c;phenylpropanoids&#x0201d;, were used, as well as names of representative compounds of these chemical groups refining with &#x0201c;antidepressant&#x0201d; or &#x0201c;depression&#x0201d;. A search was performed in the scientific literature database PubMed from 1995 to December 2015. The essential oils or the main constituents were deemed to display antidepressant activity when they had shown effects in one or more different depressant model. The scientific publications were selected from studies published in English language.</p></sec><sec id="sec4-molecules-22-01290"><title>4. Clinical Effects of Essential Oils on Mood Depression</title><p>Certain clinical studies have been aimed at investigating the effects of essential oils in humans on mood and major depression. The most frequently studied essential oil for mood states is lavender, possibly due to its previously well-recognized anxiolytic effects [<xref rid="B17-molecules-22-01290" ref-type="bibr">17</xref>]. Lavender oil capsules produced from <italic>Lavandula angustifolia</italic> Mill. (Lamiaceae) flowers were tested as an adjuvant therapy for major depression in patients under conventional pharmacological treatment [<xref rid="B28-molecules-22-01290" ref-type="bibr">28</xref>]. In this pilot study, eight patients diagnosed with major depression and symptoms of anxiety, insomnia, and psychomotor agitation were treated with lavender oil for three weeks. The results demonstrated that lavender oil reduced certain anxiety related symptoms, psychomotor agitation, and sleep disturbances in the depressed patients, thus indicating significant improvements as compared to classical antidepressant medication alone [<xref rid="B28-molecules-22-01290" ref-type="bibr">28</xref>].</p><p>The acute inhalation effects of lavender essential oil were investigated on moods in adult healthy men [<xref rid="B29-molecules-22-01290" ref-type="bibr">29</xref>]. Electroencephalogragy (EEG) activity, alertness, and mood were assessed in 40 healthy adult men given 3 min (daily) of lavender oil inhalation. The subjects showed increased EEG beta power, reported feeling more relaxed, and with less depressive moods (as scaled by Profile of Mood States (POMS)); they also performed math computations faster and more accurately [<xref rid="B29-molecules-22-01290" ref-type="bibr">29</xref>]. These findings suggest that lavender oil can improve moods even in healthy individuals.</p><p>In another clinical pilot trial, the effects of an essential oil blend of <italic>Lavandula angustifolia</italic> Mill. and <italic>Rose otto</italic> (syn. <italic>Rosa</italic> &#x000d7; <italic>damascena</italic> Mill.), Rosaceae, in 28 postpartum women diagnosed with mild to moderate depression or anxiety [<xref rid="B30-molecules-22-01290" ref-type="bibr">30</xref>]. The essential oil was administered by inhalation or using the dermal route (in a white lotion). Treatment consisted of 15 min sessions, twice a week for four consecutive weeks. The essential oils significantly relieved both depression symptoms (as scored by Edinburgh Postnatal Depression Scale (EPDS)), and anxiety (as scored by Generalized Anxiety Disorder Scale (GAD-7)). There were no adverse effects reported [<xref rid="B30-molecules-22-01290" ref-type="bibr">30</xref>]. The study supported the beneficial effects of essential oils, in this case a combination of rose and lavender oils, for relief of depression and anxiety in postpartum women. Ultimately, this clinical study proposed an interesting approach combining distinct essential oils to better treat psychiatric disorders and/or comorbid diseases.</p><p><italic>Salvia sclarea</italic> L. (Lamiaceae) essential oil was tested in a pilot trial for modulation of depression signs in 22 women [<xref rid="B31-molecules-22-01290" ref-type="bibr">31</xref>]. Normal and depressive tendencies and serum parameters in menopausal women acutely inhaling clary sage oil were assessed before and after exposition. Given the comparison between pre-inhalation and post-inhalation of clary sage oil, 5-HT plasma concentrations increased significantly, and plasma cortisol levels decreased significantly for both normal and depressive menopausal women [<xref rid="B31-molecules-22-01290" ref-type="bibr">31</xref>]. It should be mentioned that this pioneering clinical trial contributed by measuring physiological changes alongside of behavioral alterations in women with depressive symptoms after acute clary sage oil inhalation.</p><p>In a controlled, and randomized clinical pilot trial, the effect of continuous inhalation, in adult men with depression and under conventional pharmacological treatment, of citrus fragrance, (whose main component was lemon oil), was compared with that of no fragrance (n = 12 and 8, respectively) [<xref rid="B32-molecules-22-01290" ref-type="bibr">32</xref>]. Four to eleven weeks of citrus fragrance inhalation significantly improved mood states, as scored by the Symptom Distress Scale (SDS) and the Hamilton Rating Scale for Depression (HRSD). The results indicated that therapeutic dosages necessary for treatment of depression can be markedly reduced. In fact, treatments with citrus oil normalized neuro-endocrine hormone levels and immune function [<xref rid="B32-molecules-22-01290" ref-type="bibr">32</xref>]. This distinctly long-term clinical trial of citrus fragrance brings considerable insight to the beneficial effects of essential oils as therapy adjuvants for the treatment of major depression.</p></sec><sec id="sec5-molecules-22-01290"><title>5. Antidepressant-Like Effects of Essential Oils: Evidence from Animal Studies</title><p>As summarized in <xref rid="molecules-22-01290-t001" ref-type="table">Table 1</xref>, the following essential oils of plants displayed some antidepressant-like effects when tested in rodents: essential oils of <italic>Acorus tatarinowii</italic> Schott (Acoraceae), <italic>Asarum heterotropoides</italic> F. Schmidt (Aristolochiaceae), <italic>Citrus limon</italic> (L.) Osbeck (Rutaceae), <italic>Eugenia uniflora</italic> L. (Myrtaceae), <italic>Lavandula angustifolia</italic> Mill, <italic>Litsea glaucescens</italic> Kunth (Lauraceae), <italic>Mentha</italic> &#x000d7; <italic>piperita</italic> L. (Lamiaceae), <italic>Perilla frutescens</italic> (L.) Britton (Lamiaceae), <italic>Rosmarinus officinalis</italic> L. (Lamiaceae), <italic>Salvia sclarea</italic> L., <italic>Schinus terebinthifolius</italic> Raddi (Anacardiaceae), <italic>Syzygium aromaticum</italic> (L.) Merr. &#x00026; L.M. Perry (Myrtaceae), <italic>Toona ciliata</italic> Roem var. Yunnanensis (C. DC.) C.Y. Wu (Meliaceae), <italic>Valeriana wallichii</italic> DC. (Caprifoliaceae), and <italic>Zingiber officinale</italic> Roscoe (Zingiberaceae). The most promising aromatic plants with significant evidence of antidepressant-like effects and the putative mechanisms by which they act are detailed below. Indeed, the main constituents of some of these essential oils have been already isolated, identified, and even tested for antidepressant effects in rodents.</p><sec id="sec5dot1-molecules-22-01290"><title>5.1. Asarum heterotropoides <italic>F. Schmidt (Aristolochiaceae)</italic></title><p>Recently, a study showed for the first time the antidepressant-like effects of <italic>Asarum heterotropoides</italic> F. Schmidt essential oil (from the roots) in mice [<xref rid="B34-molecules-22-01290" ref-type="bibr">34</xref>]. The chemical composition of this essential oil was analyzed; 78 peaks were detected by gas chromatography. The main compounds are methyl eugenol (22%), pentadecane (6%), and 2,3,5-trimethoxytoluene (5%). Antidepressant-like effects were observed after acute inhalation in behavioral despair assays (e.g., forced swimming and tail suspension tests) in mouse. Considering the prevalence of methyl eugenol in the <italic>Asarum heterotropoides</italic> F. Schmidt essential oil, and the antidepressant-like actions previously reported about this compound in rats [<xref rid="B50-molecules-22-01290" ref-type="bibr">50</xref>], it might be suggested the methyl eugenol as the main mediator of the antidepressant effects induced by <italic>Asarum heterotropoides</italic> F. Schmidt. Immunohistochemistry was performed to investigate the mechanisms of action. An increase in the CRF- and tyrosine hidroxylase-positive cells in the paraventricular nucleus and locus coeruleus, respectively, and a significant decrease of 5-HT-positive cells was observed in the mouse dorsal raphe after forced swimming exposure. The inhalation of <italic>Asarum heterotropoides</italic> F. Schmidt essential oil restored to normal levels the immunoreactivity to 5-HT, CRF and tyrosine hidroxylase. Considering that stress-induced depression-like behaviors are closely linked to increased activity of the endogenous peptidergic system of CRF and reduced availability of monoamines [<xref rid="B51-molecules-22-01290" ref-type="bibr">51</xref>], the mechanistic findings herein reported could be on the basis of the antidepressant-like effects of <italic>Asarum heterotropoides</italic> F. Schmidt oil.</p></sec><sec id="sec5dot2-molecules-22-01290"><title>5.2. Citrus limon <italic>L. Osbeck</italic></title><p>Acute inhaled lemon oil reduced immobility time in the FST in rats and mice [<xref rid="B35-molecules-22-01290" ref-type="bibr">35</xref>,<xref rid="B36-molecules-22-01290" ref-type="bibr">36</xref>]. However, in the same studies, inhalation of this oil reduced locomotion and exploration in the open field, which would be suggestive of a sedative effect [<xref rid="B35-molecules-22-01290" ref-type="bibr">35</xref>,<xref rid="B37-molecules-22-01290" ref-type="bibr">37</xref>]. Later, Lopes et al. [<xref rid="B37-molecules-22-01290" ref-type="bibr">37</xref>] evaluated prolonged oral effects of <italic>Citrus limon</italic> L. Osbeck oil (from the leaves) in mice in the FST. Antidepressant, anxiolytic and hypolocomotor effects in animal were reported in a dose-dependent manner. A mixture of monoterpenes was detected in the <italic>Citrus limon</italic> L. Osbeck essential oil, among which limonene (53%), geranyl acetate (10%) and <italic>trans</italic>-limonene-oxide (7%) were the main compounds [<xref rid="B37-molecules-22-01290" ref-type="bibr">37</xref>]. Contrasting findings are available in literature regarding the effects of limonene on mood states in rodents. After acute administration, the monoterpene was inactive in the mouse FST [<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>]. However, under prolonged treatment (15 days), limonene reversed increased immobility time in the FST induced by neuropathic pain in rats [<xref rid="B46-molecules-22-01290" ref-type="bibr">46</xref>]. The putative mechanism by which lemon oil produces antidepressant-like effects seems to be mediated by 5-HT and dopamine neurotransmission. The pretreatment with buspirone (5-HT<sub>1A</sub> partial agonist), DOI (5-HT<sub>2A</sub> receptor agonist), miaserin (5-HT<sub>2A/C</sub> receptor agonist), apomorphin (nonselective dopamine receptor agonist) and haloperidol (nonselective dopamine receptor antagonist), blocked the antidepressant effects of lemon oil [<xref rid="B35-molecules-22-01290" ref-type="bibr">35</xref>]. Moreover, the acute inhalation of this oil significantly increased dopamine contents in the hippocampus and 5-HT in the prefrontal cortex and hippocampus [<xref rid="B35-molecules-22-01290" ref-type="bibr">35</xref>]. As commented before, dopamine and 5-HT are intrinsically involved in the modulation of mood states, and hippocampus and prefrontal cortex are the main stages of this action [<xref rid="B4-molecules-22-01290" ref-type="bibr">4</xref>]. Thus, the antidepressant-like effects of <italic>Citrus limon</italic> L. Osbeck oil might be mediated by limonene. Indeed, modulation of 5-HT and dopamine neurotransmission in brain areas highly involved with mood states could be on the basis of the antidepressant effects of lemon oil.</p></sec><sec id="sec5dot3-molecules-22-01290"><title>5.3. Eugenia uniflora <italic>L.</italic></title><p>The potential antidepressant-like effects of <italic>Eugenia uniflora</italic> L. essential oil showed in a dose-dependent manner after acute administration in the TST in mice [<xref rid="B38-molecules-22-01290" ref-type="bibr">38</xref>]. The chemical composition of <italic>Eugenia uniflora</italic> L. oil was analyzed by gas chromatography/mass spectroscopy; and it contains mainly sesquiterpenes: germacrene B (22%), selina-1,3,7-trien-8-one-oxide (19%), &#x003b2;-caryophyllene (13%), germacrene A (11%), germacrene D (11%), selina-1,3,7-trien-8-one (9%) and curzerene (4%). Only &#x003b2;-caryophyllene has been tested for the effects on depression states. The acute administration of &#x003b2;-caryophyllene induced robust antidepressant-like effects, as replicated in distinct animal models in mice: FST, TST, and novelty-suppressed feeding behavior [<xref rid="B52-molecules-22-01290" ref-type="bibr">52</xref>]. Indeed, the antidepressant effects of the isolated constituent &#x003b2;-caryophyllene were prevented by the pretreatment with a CB<sub>2</sub> receptor antagonist, AM630 [<xref rid="B52-molecules-22-01290" ref-type="bibr">52</xref>]. Interestingly, &#x003b2;-caryophyllene acts as a CB2 receptor agonist [<xref rid="B53-molecules-22-01290" ref-type="bibr">53</xref>]. The CB<sub>2</sub> receptor is expressed also in the brain, and is involved in the modulation of anxiety and depressive states [<xref rid="B54-molecules-22-01290" ref-type="bibr">54</xref>]. Victoria et al. [<xref rid="B38-molecules-22-01290" ref-type="bibr">38</xref>] showed the involvement of monoamines neurotransmission mediating the <italic>Eugenia uniflora</italic> L. oil-induced antidepressant actions. The blockade of 5-HT<sub>2A/C</sub>, &#x003b1;<sub>1</sub>- and &#x003b1;<sub>2</sub>-receptors prevented the antidepressant effects of this essential oil in the mouse TST. Additional studies aimed to investigate the effects of chronic administration of <italic>Eugenia uniflora</italic> L. oil in animal models of depression and putative mechanisms of action are worth carrying out.</p></sec><sec id="sec5dot4-molecules-22-01290"><title>5.4. Perilla frutescens <italic>L. Britton</italic></title><p>Two distinct research groups from China have described the antidepressant effects of <italic>Perilla frutescens</italic> L. Britton essential oil in mice. Using the chronic unpredictable mild stress (CUMS), a well validated animal model of depression, these studies showed the effects of the essential oil in reversing behavioral, neurochemical, and immunological alterations induced by stress [<xref rid="B42-molecules-22-01290" ref-type="bibr">42</xref>,<xref rid="B43-molecules-22-01290" ref-type="bibr">43</xref>]. The essential oil restored sucrose-preference in stressed mice, a behavior intrinsically related to anedonia, a core symptom of depression. In addition, the treatment with this oil also restored the increased immobility time in the FST and TST in CUMS mice, thus supporting a robust antidepressant-like action [<xref rid="B42-molecules-22-01290" ref-type="bibr">42</xref>,<xref rid="B43-molecules-22-01290" ref-type="bibr">43</xref>]. Changes in 5-HT and BDNF levels might be based on the antidepressant actions.</p><p>The administration of the essential oil effectively reversed the reduced hippocampal concentrations of 5-HT, its metabolite, 5-HIAA, and BDNF protein and mRNA [<xref rid="B42-molecules-22-01290" ref-type="bibr">42</xref>,<xref rid="B43-molecules-22-01290" ref-type="bibr">43</xref>]. A growing body of evidence supports the release of pro-inflammatory cytokines, mainly IL-1&#x003b2;, IL-6, and TNF-&#x003b1;, in major depression [<xref rid="B55-molecules-22-01290" ref-type="bibr">55</xref>]. The chronic administration of <italic>Perilla frutescens</italic> L. Britton oil dose-dependently decreased the serum IL-6, IL-1&#x003b2;, and TNF-<italic>&#x003b1;</italic> levels in CUMS-mice. The main constituents of this essential oil extracted by supercritical fluid are <sc>l</sc>-perillaldehyde, limonene, beta-caryophyllene, selinene, santalene and bergamotene [<xref rid="B56-molecules-22-01290" ref-type="bibr">56</xref>]. <sc>l</sc>-perillaldehyde-induced antidepressant-like effects have already been reported in mice [<xref rid="B42-molecules-22-01290" ref-type="bibr">42</xref>,<xref rid="B57-molecules-22-01290" ref-type="bibr">57</xref>]. Repeated administration (oral and inhalated) of this compound reversed depressant-like behaviors induced by CUMS and lipopolyssacaride (LPS) [<xref rid="B42-molecules-22-01290" ref-type="bibr">42</xref>,<xref rid="B57-molecules-22-01290" ref-type="bibr">57</xref>]. Concerning the mechanism of action of <sc>l</sc>-perillaldehyde on depressive states, restored concentrations of 5-HT and noradrenaline in the prefrontal cortex were observed in LPS-treated mice, and attenuated LPS-induced increases of TNF-&#x003b1; and IL-6 levels [<xref rid="B42-molecules-22-01290" ref-type="bibr">42</xref>]. The <italic>Perilla frutescens</italic> L. Britton oil has other compounds with antidepressant-like actions, such as limonene and beta-caryophyllene [<xref rid="B46-molecules-22-01290" ref-type="bibr">46</xref>,<xref rid="B52-molecules-22-01290" ref-type="bibr">52</xref>]. Taken together, the robust antidepressant effects of <italic>Perilla frutescens</italic> L. Britton oil suggest that more than one active compound, with distinct mechanisms of action, could be mediating this effect.</p></sec><sec id="sec5dot5-molecules-22-01290"><title>5.5. Salvia sclarea <italic>L.</italic></title><p>The antidepressant effects of essential oil of <italic>Salvia sclarea</italic> L. were assessed in the FST in rats. The acute exposition to this oil, via intraperitoneal and inhalation, reduced immobility time similar to conventional antidepressant drugs [<xref rid="B39-molecules-22-01290" ref-type="bibr">39</xref>]. The antidepressant effects of this essential oil seem to be mainly mediated by the activation of dopamine and 5-HT neurotransmission [<xref rid="B39-molecules-22-01290" ref-type="bibr">39</xref>]. In fact, the pretreatment with haloperidol (Dopamine receptor antagonist), SCH-23390 (D<sub>1</sub> receptor antagonist), but also buspirone (5-HT<sub>1A</sub> partial agonist) blocked the antidepressant effect of this essential oil [<xref rid="B39-molecules-22-01290" ref-type="bibr">39</xref>]. The principal constituents of <italic>Salvia sclarea</italic> L. oil include linalyl acetate (64%), linalool (21%), and geraniol (2.6%) [<xref rid="B32-molecules-22-01290" ref-type="bibr">32</xref>]. Linalool and geraniol have showed consistent antidepressant actions in rodents after acute administrations [<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>,<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>,<xref rid="B59-molecules-22-01290" ref-type="bibr">59</xref>,<xref rid="B60-molecules-22-01290" ref-type="bibr">60</xref>]. This effect of linalool in rodents were prevented with WAY100,635 (5-HT<sub>1A</sub> receptor antagonist) and yohimbine (&#x003b1;<sub>2</sub>-receptor antagonist), thus reinforcing the role mediated by monoaminergic neurotransmission in the antidepressant effects of linalool [<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>]. Ultimately, the antidepressant of the <italic>Salvia sclarea</italic> L. essential oil seems to be due to the synergic effects of bioactive isolated compounds.</p></sec><sec id="sec5dot6-molecules-22-01290"><title>5.6. Syzygium aromaticum <italic>(L.) Merr. &#x00026; L.M. Perry</italic></title><p>Recently, a well-designed study showed the antidepressant effects of <italic>S. aromaticum</italic> essential oil in rodents. After acute administration, this essential oil reduced immobility time in mice in the FST and TST. Using the CUMS, chronic administration of <italic>S. aromaticum</italic> (L.) Merr. &#x00026; L.M. Perry oil restored sucrose preference and reversed the increased latency to feed in an unfamiliar environment in CUMS rats [<xref rid="B47-molecules-22-01290" ref-type="bibr">47</xref>]. The antidepressant doses (50&#x02013;200 mg/kg) were, at least, 22-fold higher than the lethal dose 53 (LD<sub>50</sub> = 4.5 g/kg). The chronic administration of this essential oil restored hippocampal BDNF, p-ERK and p-CREB protein expression in CUMS rats [<xref rid="B47-molecules-22-01290" ref-type="bibr">47</xref>]. The major compounds identified in <italic>S. aromaticum</italic> (L.) Merr. &#x00026; L.M. Perry essential oil were eugenol (71%), &#x003b2;-caryophyllene (10%), eugenyl acetate (16%) [<xref rid="B47-molecules-22-01290" ref-type="bibr">47</xref>]. Literature findings support antidepressant-like actions for eugenol and &#x003b2;-caryophyllene [<xref rid="B52-molecules-22-01290" ref-type="bibr">52</xref>,<xref rid="B61-molecules-22-01290" ref-type="bibr">61</xref>,<xref rid="B62-molecules-22-01290" ref-type="bibr">62</xref>], which could be synergically mediating the antidepressant effects of the <italic>S. aromaticum</italic> (L.) Merr. &#x00026; L.M. Perry oil. Repeated administration of eugenol reduced immobility in the TST and FST [<xref rid="B61-molecules-22-01290" ref-type="bibr">61</xref>,<xref rid="B62-molecules-22-01290" ref-type="bibr">62</xref>]. The antidepressant effects of eugenol were attributed to the inhibition of human MAO<sub>A</sub> [<xref rid="B60-molecules-22-01290" ref-type="bibr">60</xref>], and the increase in hippocampal BDNF [<xref rid="B61-molecules-22-01290" ref-type="bibr">61</xref>]. These findings suggest that eugenol, but also &#x003b2;-caryophyllene could be mediating the antidepressant-like actions of <italic>S. aromaticum</italic> (L.) Merr. &#x00026; L.M. Perry essential oil by the increase in monoamine neurotransmission and neuroplastic actions.</p></sec><sec id="sec5dot7-molecules-22-01290"><title>5.7. Toona ciliata <italic>var.</italic> yunnanensis <italic>(C. DC.) C.Y. Wu</italic></title><p>The acute administration of <italic>T. ciliata</italic> var. Yunnanensis (C. DC.) C.Y. Wu oil evoked antidepressant-like actions in a dose-dependent manner in mice, in the FST and TST [<xref rid="B48-molecules-22-01290" ref-type="bibr">48</xref>]. In addition, the treatment with this essential oil increased hippocampal monoamines (5-HT, noradrenaline and dopamine) and BDNF contents in CUMS rats [<xref rid="B48-molecules-22-01290" ref-type="bibr">48</xref>]. The major compounds identified in <italic>T. ciliata</italic> var. Yunnanensis (C. DC.) C.Y. Wu oil by gas chromatography/mass spectroscopy were &#x003b2;-elemene (25%), &#x003b2;-cubebene (14%), &#x003b3;-elemene (8%), and estragole (6%) [<xref rid="B48-molecules-22-01290" ref-type="bibr">48</xref>]. None of these components have been tested yet for the effects on depressive states. Further studies aimed to evaluate the effects of the isolated oil compounds and the <italic>T. ciliata</italic> var. Yunnanensis (C. DC.) C.Y. Wu oil during chronic administration in animal models of depression are warranted.</p></sec><sec id="sec5dot8-molecules-22-01290"><title>5.8. Valeriana wallichii <italic>DC.</italic></title><p>The effects of <italic>Valeriana wallichii</italic> DC. (patchouli alcohol chemotype) were tested in the mouse FST after acute and 14-days administration [<xref rid="B49-molecules-22-01290" ref-type="bibr">49</xref>]. The acute treatment with this essential oil reduced, in a dose-dependent manner, the immobility time of mice in the FST; the antidepressant doses in this assay were 20 mg/kg and 40 mg/kg [<xref rid="B49-molecules-22-01290" ref-type="bibr">49</xref>]. However, after repeated administration, the <italic>V. wallichii</italic> DC. oil reduced immobility time only at 20 mg/kg [<xref rid="B49-molecules-22-01290" ref-type="bibr">49</xref>]. Chronic administration increased norepinephrine and 5-HT levels in the mouse brain [<xref rid="B61-molecules-22-01290" ref-type="bibr">61</xref>]. More evidence suggests the participation of nitric oxide signaling pathway in the acute antidepressant-like effect of <italic>V. wallichii</italic> DC. essential oil. The pretreatment with <sc>l</sc>-arginine (NO precursor) and sildenafil (phosphodiesterase 5 inhibitor) prevented the antidepressant effect, while it was potentiated with L-NAME (NOS inhibitor), and methylene blue (inhibitor of soluble guanylate cyclase) [<xref rid="B49-molecules-22-01290" ref-type="bibr">49</xref>]. These findings are in accordance with previous studies that showed reduction of NO levels within the brain inducing antidepressant-like effects [<xref rid="B63-molecules-22-01290" ref-type="bibr">63</xref>,<xref rid="B64-molecules-22-01290" ref-type="bibr">64</xref>,<xref rid="B65-molecules-22-01290" ref-type="bibr">65</xref>]. Classical antidepressant drugs induce behavioral effects in the FST via blockade of nitregic system pathway [<xref rid="B66-molecules-22-01290" ref-type="bibr">66</xref>,<xref rid="B67-molecules-22-01290" ref-type="bibr">67</xref>]. The <italic>V. wallichii</italic> DC. oil constituents were identified by gas chromatography-mass spectroscopy. The oil contains patchouli alcohol (40%) as the major constituent followed by the presence of &#x003b4;-guaiene (10%), seychellene (8%), 8-acetoxyl patchouli alcohol (4%) and virdiflorol (5%). These isolated compounds have not still tested on experimental depression. Further studies, aimed at investigating the effects of these isolated compounds as well as the effects of <italic>V. wallichii</italic> DC. essential oil on depression in rodents, are needed [<xref rid="B49-molecules-22-01290" ref-type="bibr">49</xref>].</p></sec></sec><sec id="sec6-molecules-22-01290"><title>6. Constituents from Essential Oils with Antidepressant-Like Activity</title><p>The effects of isolated compounds from essential oils in the rodent behavior are summarized in <xref rid="molecules-22-01290-t002" ref-type="table">Table 2</xref>.</p><sec id="sec6dot1-molecules-22-01290"><title>6.1. Isolated Constituents with Proposed Mechanisms of Antidepressant Action</title><p>The most studied isolated compounds are eugenol [<xref rid="B61-molecules-22-01290" ref-type="bibr">61</xref>,<xref rid="B62-molecules-22-01290" ref-type="bibr">62</xref>] and linalool [<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>,<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>,<xref rid="B59-molecules-22-01290" ref-type="bibr">59</xref>]. Studies suggest robust antidepressant-like actions as demonstrated in distinct behavioral tests (FST and TST) performed in different labs around the world. The main target of the antidepressant action of eugenol is the MAO enzyme [<xref rid="B62-molecules-22-01290" ref-type="bibr">62</xref>]. This compound preferentially inhibits the MAO<sub>A</sub> activity, and after chronic administrations increases the neurotrophic factor, BDNF, a mechanism of action shared with conventional antidepressants [<xref rid="B4-molecules-22-01290" ref-type="bibr">4</xref>]. Concerning linalool, main constituent of the extracted lavender and clary sage oil [<xref rid="B31-molecules-22-01290" ref-type="bibr">31</xref>,<xref rid="B76-molecules-22-01290" ref-type="bibr">76</xref>], acute studies suggestive of antidepressant actions support the activation of monoamine 5-HT<sub>1A</sub> and &#x003b1;<sub>2</sub>-receptors [<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>].</p><p>Other isolated constituents from essential oils that induce antidepressant-like actions possibly mediated by monoamines are <sc>l</sc>-menthone [<xref rid="B72-molecules-22-01290" ref-type="bibr">72</xref>], perillaldehyde [<xref rid="B57-molecules-22-01290" ref-type="bibr">57</xref>], thymol [<xref rid="B73-molecules-22-01290" ref-type="bibr">73</xref>] and thymoquinone [<xref rid="B74-molecules-22-01290" ref-type="bibr">74</xref>]. These compounds increase monoamines in the brain, a mechanism of action similar to classical antidepressants. Studies showed that carvacrol and &#x003b2;-pinene induce antidepressant-like actions in behavioral despair assays, e.g., FST and TST [<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>,<xref rid="B68-molecules-22-01290" ref-type="bibr">68</xref>]. The acute treatment with these isolated constituents decrease the immobility time, an effect reversed by the pretreatment with SCH23390, a dopamine D<sub>1</sub> antagonist [<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>,<xref rid="B68-molecules-22-01290" ref-type="bibr">68</xref>]. The antidepressant effects of &#x003b2;-pinene were also blocked by 5-HT<sub>1A</sub> antagonist, &#x003b2;-antagonist and DSP-4, a noradrenergic neurotoxin [<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>]. By contrast, the pretreatment with prazosin, a &#x003b1;<sub>1</sub>-receptor antagonist, yohimbine, a &#x003b1;<sub>2</sub>-receptor antagonist, and PCPA, a 5-HT synthesis inhibitor, did not affect the antidepressant effects of carvacrol [<xref rid="B68-molecules-22-01290" ref-type="bibr">68</xref>]. These experimental data suggest that &#x003b2;-pinene seems to evoke antidepressant actions dependent on dopaminergic, serotoninergic and noradrenergic systems, while carvacrol displays antidepressant activity mainly mediated by dopaminergic system.</p><p>Some other promising isolated compounds from essential oils, such as <sc>l</sc>-menthone [<xref rid="B72-molecules-22-01290" ref-type="bibr">72</xref>], thymol [<xref rid="B73-molecules-22-01290" ref-type="bibr">73</xref>] and geraniol [<xref rid="B47-molecules-22-01290" ref-type="bibr">47</xref>] induce antidepressant-like effects in rodents and the mechanisms of these actions were partially described. For these compounds, potential anti-inflammatory effects may be involved and/or mediating the antidepressant actions. A growing number of preclinical and clinical studies have demonstrated an association between concentrations of pro-inflammatory cytokines&#x02014;mainly interleukin (IL)-1&#x003b2;, IL-6, and tumor necrosis factor-&#x003b1; and depressive symptoms. In addition, mounting evidence has shown a concomitant reduction in both depressive symptoms and pro-inflammatory cytokine concentrations following treatment with anti-inflammatory drugs [<xref rid="B77-molecules-22-01290" ref-type="bibr">77</xref>]. In this view, <sc>l</sc>-menthone, thymol and geraniol inhibited IL-1&#x003b2;, IL-6 and TNF&#x003b1; cytokines and other pro-inflammatory intracellular signaling, such as NF-&#x003ba;B, NLRP3 and caspase 1, usually increased by stress. Interestingly, the antidepressant fluoxetine could restore CUMS-induced depression-like behavior in mice by significantly decreasing the level of NLRP3 and caspase 1 [<xref rid="B77-molecules-22-01290" ref-type="bibr">77</xref>].</p><p>Cinnamic aldehyde reversed the loss of sucrose preference in CUMS rats and also reversed the increased COX-2 hippocampal expression and enzyme activity. However, no behavioral effects have been observed when mice injected with cinnamic aldehyde were subjected in the FST [<xref rid="B78-molecules-22-01290" ref-type="bibr">78</xref>]. Restoration of PGE<sub>2</sub> concentration in frontal cortex and hippocampus of stressed rats was also found in cinnamic aldehyde-treated animals [<xref rid="B69-molecules-22-01290" ref-type="bibr">69</xref>]. It is interesting to mention that some of these compounds display notable anti-inflammatory actions, such as thymol [<xref rid="B79-molecules-22-01290" ref-type="bibr">79</xref>] and geraniol [<xref rid="B80-molecules-22-01290" ref-type="bibr">80</xref>], while others induce peripheral pro-inflammatory effects, e.g., cinnamic aldehyde [<xref rid="B81-molecules-22-01290" ref-type="bibr">81</xref>]. Taken together, it is still unknown if a putative central nervous system anti-inflammatory effect is required for the antidepressant action of conventional drugs. However, further studies aimed to identify the molecular site of action of these compounds are mandatory.</p><p>Considering that most isolated constituents share a monoaminergic and/or pro-inflammatory mechanism of antidepressant action, it could be suggested that these compounds may present some chemical similarities, thus supporting an interaction with the same molecular site of action. However, the diversity of chemical structures of these compounds makes it difficult to establish a chemical template determining the antidepressant activity. This fact can be explained due to possible distinct molecular sites of action, or formation of psychoactive metabolite products.</p></sec><sec id="sec6dot2-molecules-22-01290"><title>6.2. Isolated Constituents without Antidepressant Mechanism of Action</title><p>Vanillin a constituent of essential oils used in cooking because of its pleasant odor and flavor to the food. This constituent reduced immobility duration in the FST and TST in mice after oral acutely administration. Chronic oral treatment with vanillin reduced immobility time in mice at significantly lower levels when compared to fluoxetine [<xref rid="B75-molecules-22-01290" ref-type="bibr">75</xref>].</p><p>&#x003b1;-Asarone and &#x003b2;-asarone are found in several essential oils, including as major components from the rhizome essential oil of <italic>Acorus tatarinowii</italic> Schott. These isolated compounds as well the <italic>Acorus tatarinowii</italic> Schott essential oil displays antidepressant-like effect in the FST and TST [<xref rid="B33-molecules-22-01290" ref-type="bibr">33</xref>]. No details about the antidepressant mechanisms of action of these isolated constituents were already proposed. Two other isolated constituents, limonene and &#x003b1;-phellandrene, reversed the depressant-like behavior and reduced nociceptive responses in rodents subjected to a model of neurophatic pain [<xref rid="B46-molecules-22-01290" ref-type="bibr">46</xref>]. These effects are quite interesting and should be further investigated, since chronic pain is a common comorbidity of major depressive patients.</p></sec></sec><sec id="sec7-molecules-22-01290"><title>7. Conclusions</title><p>The antidepressant effects of essential oils and their constituents are very promising but they are still at the preliminary stages. Few clinical trials have been performed until now, and most of them are aimed for testing the effects of lavender oil. Importantly, the preclinical effects of lavender oil on rodents were superficially studied, and there is no suggestion of mechanism of action for this antidepressant effect. By contrast, some essential oil constituents display promising antidepressant effects by involving monoamine neurotransmission. With respect to the attribution of the antidepressant effect of a whole essential oil to one single constituent, the overall conclusion remains that the diversity of chemically active constituents of essential oils can be an advantage in the treatment of depression, since more than one compound with positive effects on depression can evoke synergic actions. Finally, the importance of these preclinical observations for the clinical overall picture of depression still needs to be addressed through further research. Future clinical trials will give scientific support for the employment of essential oils with potential antidepressant actions as real options for the treatment of depressive states.</p></sec></body><back><ack><title>Acknowledgments</title><p>This research was supported by Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq) and Coordena&#x000e7;&#x000e3;o de Aperfei&#x000e7;oamento de Pessoal de N&#x000ed;vel Superior (CAPES).</p></ack><notes><title>Author Contributions</title><p>R.H.N.S. and E.F.d.S. revised the literature and prepared the tables. D.P.d.S and E.C.G. prepared and revised the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-molecules-22-01290"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Press (APA)</collab></person-group><source>Diagnostic and Statistical Manual of Mental Disorders</source><edition>5th ed.</edition><publisher-name>American Psychiatric Press</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><year>2013</year></element-citation></ref><ref id="B2-molecules-22-01290"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>A.J.</given-names></name><name><surname>Somerville</surname><given-names>A.J.</given-names></name><name><surname>Baxter</surname><given-names>A.J.</given-names></name><name><surname>Norman</surname><given-names>R.</given-names></name><name><surname>Patten</surname><given-names>S.B.</given-names></name><name><surname>Vos</surname><given-names>T.</given-names></name><name><surname>Whiteford</surname><given-names>H.A.</given-names></name></person-group><article-title>Global variation in the prevalence and incidence of major depressive disorder: A systematic review of the epidemiological literature</article-title><source>Psychol. Med.</source><year>2013</year><volume>43</volume><fpage>471</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1017/S0033291712001511</pub-id><?supplied-pmid 22831756?><pub-id pub-id-type="pmid">22831756</pub-id></element-citation></ref><ref id="B3-molecules-22-01290"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeroff</surname><given-names>C.B.</given-names></name><name><surname>Owens</surname><given-names>M.J.</given-names></name></person-group><article-title>Treatment of mood disorders</article-title><source>Nat. Neurosci.</source><year>2002</year><volume>5</volume><fpage>1068</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1038/nn943</pub-id><?supplied-pmid 12403988?><pub-id pub-id-type="pmid">12403988</pub-id></element-citation></ref><ref id="B4-molecules-22-01290"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castr&#x000e9;n</surname><given-names>E.</given-names></name></person-group><article-title>Is mood chemistry?</article-title><source>Nat. Rev. Neurosci.</source><year>2005</year><volume>6</volume><fpage>241</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1038/nrn1629</pub-id><?supplied-pmid 15738959?><pub-id pub-id-type="pmid">15738959</pub-id></element-citation></ref><ref id="B5-molecules-22-01290"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bj&#x000f6;rkholm</surname><given-names>C.</given-names></name><name><surname>Monteggia</surname><given-names>L.M.</given-names></name></person-group><article-title>BDNF&#x02014;A key transducer of antidepressant effects</article-title><source>Neuropharmacology</source><year>2016</year><volume>102</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.10.034</pub-id><?supplied-pmid 26519901?><pub-id pub-id-type="pmid">26519901</pub-id></element-citation></ref><ref id="B6-molecules-22-01290"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarelli</surname><given-names>L.</given-names></name><name><surname>Saxe</surname><given-names>M.</given-names></name><name><surname>Gross</surname><given-names>C.</given-names></name><name><surname>Sunget</surname><given-names>A.</given-names></name><name><surname>Battaglia</surname><given-names>F.</given-names></name><name><surname>Dulawa</surname><given-names>S.</given-names></name><name><surname>Weisstaub</surname><given-names>N.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Duman</surname><given-names>R.</given-names></name><name><surname>Arancio</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants</article-title><source>Science</source><year>2003</year><volume>301</volume><fpage>805</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1126/science.1083328</pub-id><?supplied-pmid 12907793?><pub-id pub-id-type="pmid">12907793</pub-id></element-citation></ref><ref id="B7-molecules-22-01290"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berton</surname><given-names>O.</given-names></name><name><surname>Nestler</surname><given-names>E.J.</given-names></name></person-group><article-title>New approaches to antidepressant drug discovery: Beyond monoamines</article-title><source>Nat. Rev. Neuroscience</source><year>2006</year><volume>7</volume><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/nrn1846</pub-id><?supplied-pmid 16429123?><pub-id pub-id-type="pmid">16429123</pub-id></element-citation></ref><ref id="B8-molecules-22-01290"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezerra</surname><given-names>D.P.</given-names></name><name><surname>Soares</surname><given-names>A.K.</given-names></name><name><surname>De Sousa</surname><given-names>D.P.</given-names></name></person-group><article-title>Overview of the role of vanillin on redox status and cancer development</article-title><source>Oxid. Med. Cell. Longev.</source><year>2016</year><volume>2016</volume><fpage>9734816</fpage><pub-id pub-id-type="doi">10.1155/2016/9734816</pub-id><?supplied-pmid 28077989?><pub-id pub-id-type="pmid">28077989</pub-id></element-citation></ref><ref id="B9-molecules-22-01290"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souto-Maior</surname><given-names>F.N.</given-names></name><name><surname>Fons&#x000ea;ca</surname><given-names>D.V.</given-names></name><name><surname>Salgado</surname><given-names>P.R.</given-names></name><name><surname>Monte</surname><given-names>L.O.</given-names></name><name><surname>de Sousa</surname><given-names>D.P.</given-names></name><name><surname>de Almeida</surname><given-names>R.N.</given-names></name></person-group><article-title>Antinociceptive and anticonvulsant effects of the monoterpene linalool oxide</article-title><source>Pharm. Biol.</source><year>2017</year><volume>55</volume><fpage>63</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1080/13880209.2016.1228682</pub-id><?supplied-pmid 27622736?><pub-id pub-id-type="pmid">27622736</pub-id></element-citation></ref><ref id="B10-molecules-22-01290"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sousa</surname><given-names>D.P.</given-names></name><name><surname>Lima</surname><given-names>T.C.</given-names></name><name><surname>Steverding</surname><given-names>D.</given-names></name></person-group><article-title>Evaluation of antiparasitc activity of <italic>Mentha crispa</italic> essential oil, its major constituent rotundifolone and analogues against <italic>Trypanosoma brucei</italic></article-title><source>Planta Med.</source><year>2016</year><volume>82</volume><fpage>1346</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1055/s-0042-107082</pub-id><?supplied-pmid 27220072?><pub-id pub-id-type="pmid">27220072</pub-id></element-citation></ref><ref id="B11-molecules-22-01290"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sousa</surname><given-names>D.P.</given-names></name><name><surname>de Almeida Soares Hocayen</surname><given-names>P.</given-names></name><name><surname>Andrade</surname><given-names>L.N.</given-names></name><name><surname>Andreatini</surname><given-names>R.</given-names></name></person-group><article-title>A Systematic review of the anxiolytic-like effects of essential oils in animal models</article-title><source>Molecules</source><year>2015</year><volume>20</volume><fpage>18620</fpage><lpage>18660</lpage><pub-id pub-id-type="doi">10.3390/molecules201018620</pub-id><?supplied-pmid 26473822?><pub-id pub-id-type="pmid">26473822</pub-id></element-citation></ref><ref id="B12-molecules-22-01290"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Hur</surname><given-names>M.H.</given-names></name></person-group><article-title>Inhalation effects of aroma essential oil on quality of sleep for shift nurses after night work</article-title><source>J. Korean Acad. Nurs.</source><year>2016</year><volume>46</volume><fpage>769</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.4040/jkan.2016.46.6.769</pub-id><?supplied-pmid 28077825?><pub-id pub-id-type="pmid">28077825</pub-id></element-citation></ref><ref id="B13-molecules-22-01290"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lytle</surname><given-names>J.</given-names></name><name><surname>Mwatha</surname><given-names>C.</given-names></name><name><surname>Davis</surname><given-names>K.K.</given-names></name></person-group><article-title>Effect of lavender aromatherapy on vital signs and perceived quality of sleep in the intermediate care unit: A pilot study</article-title><source>Am. J. Crit. Care</source><year>2014</year><volume>23</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.4037/ajcc2014958</pub-id><?supplied-pmid 24382614?><pub-id pub-id-type="pmid">24382614</pub-id></element-citation></ref><ref id="B14-molecules-22-01290"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Press-Sandler</surname><given-names>O.</given-names></name><name><surname>Freud</surname><given-names>T.</given-names></name><name><surname>Volkov</surname><given-names>I.</given-names></name><name><surname>Peleg</surname><given-names>R.</given-names></name><name><surname>Press</surname><given-names>Y.</given-names></name></person-group><article-title>Aromatherapy for the Treatment of Patients with Behavioral and Psychological Symptoms of Dementia: A Descriptive Analysis of RCTs</article-title><source>J. Altern. Complement. Med.</source><year>2016</year><volume>22</volume><fpage>422</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1089/acm.2015.0186</pub-id><?supplied-pmid 27159213?><pub-id pub-id-type="pmid">27159213</pub-id></element-citation></ref><ref id="B15-molecules-22-01290"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forrester</surname><given-names>L.T.</given-names></name><name><surname>Maayan</surname><given-names>N.</given-names></name><name><surname>Orrell</surname><given-names>M.</given-names></name><name><surname>Spector</surname><given-names>A.E.</given-names></name><name><surname>Buchan</surname><given-names>L.D.</given-names></name><name><surname>Soares-Weiser</surname><given-names>K.</given-names></name></person-group><article-title>Aromatherapy for dementia</article-title><source>Cochrane Database Syst. Rev.</source><year>2014</year><volume>2</volume><fpage>CD003150</fpage></element-citation></ref><ref id="B16-molecules-22-01290"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>S.</given-names></name><name><surname>Jacob</surname><given-names>T.J.</given-names></name></person-group><article-title>Combined non-adaptive light and smell stimuli lowered blood pressure, reduced heart rate and reduced negative affect</article-title><source>Physiol. Behav.</source><year>2016</year><volume>156</volume><fpage>94</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2016.01.013</pub-id><?supplied-pmid 26780148?><pub-id pub-id-type="pmid">26780148</pub-id></element-citation></ref><ref id="B17-molecules-22-01290"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasper</surname><given-names>S.</given-names></name><name><surname>Anghelescu</surname><given-names>I.</given-names></name><name><surname>Dienel</surname><given-names>A.</given-names></name></person-group><article-title>Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep&#x02014;A randomized, placebo-controlled trial</article-title><source>Eur. Neuropsychopharmacol.</source><year>2015</year><volume>25</volume><fpage>1960</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2015.07.024</pub-id><?supplied-pmid 26293583?><pub-id pub-id-type="pmid">26293583</pub-id></element-citation></ref><ref id="B18-molecules-22-01290"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordell</surname><given-names>B.</given-names></name><name><surname>Buckle</surname><given-names>J.</given-names></name></person-group><article-title>The effects of aromatherapy on nicotine craving on a U.S. campus: A small comparison study</article-title><source>J. Altern. Complement. Med.</source><year>2013</year><volume>19</volume><fpage>709</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1089/acm.2012.0537</pub-id><?supplied-pmid 23536963?><pub-id pub-id-type="pmid">23536963</pub-id></element-citation></ref><ref id="B19-molecules-22-01290"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uehleke</surname><given-names>B.</given-names></name><name><surname>Schaper</surname><given-names>S.</given-names></name><name><surname>Dienel</surname><given-names>A.</given-names></name><name><surname>Schlaefke</surname><given-names>S.</given-names></name><name><surname>Stange</surname><given-names>R.</given-names></name></person-group><article-title>Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder</article-title><source>Phytomedicine</source><year>2012</year><volume>19</volume><fpage>665</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2012.02.020</pub-id><?supplied-pmid 22475718?><pub-id pub-id-type="pmid">22475718</pub-id></element-citation></ref><ref id="B20-molecules-22-01290"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimbo</surname><given-names>D.</given-names></name><name><surname>Kimura</surname><given-names>Y.</given-names></name><name><surname>Taniguchi</surname><given-names>M.</given-names></name><name><surname>Inoue</surname><given-names>M.</given-names></name><name><surname>Urakami</surname><given-names>K.</given-names></name></person-group><article-title>Effect of aromatherapy on patients with Alzheimer&#x02019;s disease</article-title><source>Psychogeriatrics</source><year>2009</year><volume>9</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1111/j.1479-8301.2009.00299.x</pub-id><?supplied-pmid 20377818?><pub-id pub-id-type="pmid">20377818</pub-id></element-citation></ref><ref id="B21-molecules-22-01290"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sousa</surname><given-names>D.P.</given-names></name></person-group><article-title>Analgesic-like activity of essential oils constituents</article-title><source>Molecules</source><year>2011</year><volume>16</volume><fpage>2233</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.3390/molecules16032233</pub-id><?supplied-pmid 21383660?><pub-id pub-id-type="pmid">21383660</pub-id></element-citation></ref><ref id="B22-molecules-22-01290"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>De Sousa</surname><given-names>D.P.</given-names></name></person-group><source>Bioactive Essential Oils and Cancer</source><publisher-name>Springer International Publishing</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2015</year></element-citation></ref><ref id="B23-molecules-22-01290"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>F.A.</given-names></name><name><surname>Andrade</surname><given-names>L.N.</given-names></name><name><surname>De Sousa</surname><given-names>E.B.</given-names></name><name><surname>De Sousa</surname><given-names>D.P.</given-names></name></person-group><article-title>Anti-ulcer activity of essential oil constituents</article-title><source>Molecules</source><year>2014</year><volume>19</volume><fpage>5717</fpage><lpage>5747</lpage><pub-id pub-id-type="doi">10.3390/molecules19055717</pub-id><?supplied-pmid 24802985?><pub-id pub-id-type="pmid">24802985</pub-id></element-citation></ref><ref id="B24-molecules-22-01290"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobral</surname><given-names>M.V.</given-names></name><name><surname>Xavier</surname><given-names>A.L.</given-names></name><name><surname>Lima</surname><given-names>T.C.</given-names></name><name><surname>De Sousa</surname><given-names>D.P.</given-names></name></person-group><article-title>Antitumor activity of monoterpenes found in essential oils</article-title><source>Sci. World J.</source><year>2014</year><volume>2014</volume><fpage>953451</fpage><pub-id pub-id-type="doi">10.1155/2014/953451</pub-id><?supplied-pmid 25401162?><pub-id pub-id-type="pmid">25401162</pub-id></element-citation></ref><ref id="B25-molecules-22-01290"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yim</surname><given-names>V.W.</given-names></name><name><surname>Ng</surname><given-names>A.K.</given-names></name><name><surname>Tsang</surname><given-names>H.W.</given-names></name><name><surname>Leung</surname><given-names>A.Y.</given-names></name></person-group><article-title>A review on the effects of aromatherapy for patients with depressive symptoms</article-title><source>J. Altern. Complement. Med.</source><year>2009</year><volume>15</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1089/acm.2008.0333</pub-id><?supplied-pmid 19216657?><pub-id pub-id-type="pmid">19216657</pub-id></element-citation></ref><ref id="B26-molecules-22-01290"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.L.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Tsang</surname><given-names>H.W.</given-names></name><name><surname>Leung</surname><given-names>A.Y.</given-names></name><name><surname>Cheung</surname><given-names>W.M.</given-names></name></person-group><article-title>A systematic review on the anxiolytic effects of aromatherapy in people with anxiety symptoms</article-title><source>J. Altern. Complement. Med.</source><year>2011</year><volume>17</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1089/acm.2009.0277</pub-id><?supplied-pmid 21309711?><pub-id pub-id-type="pmid">21309711</pub-id></element-citation></ref><ref id="B27-molecules-22-01290"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setzer</surname><given-names>W.N.</given-names></name></person-group><article-title>Essential oils and anxiolytic aromatherapy</article-title><source>Nat. Prod. Commun.</source><year>2009</year><volume>4</volume><fpage>1305</fpage><lpage>1316</lpage><?supplied-pmid 19831048?><pub-id pub-id-type="pmid">19831048</pub-id></element-citation></ref><ref id="B28-molecules-22-01290"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fibler</surname><given-names>M.</given-names></name><name><surname>Quante</surname><given-names>A.</given-names></name></person-group><article-title>A case series on the use of lavendula oil capsules in patients suffering from major depressive disorder and symptoms of psychomotor agitation, insomnia and anxiety</article-title><source>Complement. Ther. Med.</source><year>2014</year><volume>22</volume><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">24559818</pub-id></element-citation></ref><ref id="B29-molecules-22-01290"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diego</surname><given-names>M.A.</given-names></name><name><surname>Jones</surname><given-names>N.A.</given-names></name><name><surname>Field</surname><given-names>T.</given-names></name><name><surname>Hernandez-Reif</surname><given-names>M.</given-names></name><name><surname>Schanberg</surname><given-names>S.</given-names></name><name><surname>Kuhn</surname><given-names>C.</given-names></name><name><surname>McAdam</surname><given-names>V.</given-names></name><name><surname>Galamaga</surname><given-names>R.</given-names></name><name><surname>Galamaga</surname><given-names>M.</given-names></name></person-group><article-title>Aromatherapy positively affects mood, EEG patterns falertness and math computations</article-title><source>Int. J. Neurosci.</source><year>1998</year><volume>96</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.3109/00207459808986469</pub-id><?supplied-pmid 10069621?><pub-id pub-id-type="pmid">10069621</pub-id></element-citation></ref><ref id="B30-molecules-22-01290"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname><given-names>P.</given-names></name><name><surname>Adams</surname><given-names>C.</given-names></name></person-group><article-title>The effects of clinical aromatherapy for anxiety and depression in the high risk postpartum woman&#x02014;A pilot study</article-title><source>Complement. Ther. Clin. Pract.</source><year>2012</year><volume>18</volume><fpage>164</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.ctcp.2012.05.002</pub-id><?supplied-pmid 22789792?><pub-id pub-id-type="pmid">22789792</pub-id></element-citation></ref><ref id="B31-molecules-22-01290"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K.B.</given-names></name><name><surname>Cho</surname><given-names>E.</given-names></name><name><surname>Kang</surname><given-names>Y.S.</given-names></name></person-group><article-title>Changes in 5-hydroxytryptamine and cortisol plasma levels in menopausal women after inhalation of clary sage oil</article-title><source>Phytother. Res.</source><year>2014</year><volume>28</volume><fpage>1599</fpage><lpage>1605</lpage><pub-id pub-id-type="doi">10.1002/ptr.5163</pub-id><?supplied-pmid 24802524?><pub-id pub-id-type="pmid">24802524</pub-id></element-citation></ref><ref id="B32-molecules-22-01290"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komori</surname><given-names>T.</given-names></name><name><surname>Fujiwara</surname><given-names>R.</given-names></name><name><surname>Tanida</surname><given-names>M.</given-names></name><name><surname>Nomura</surname><given-names>J.</given-names></name><name><surname>Yokoyama</surname><given-names>M.M.</given-names></name></person-group><article-title>Effects of citrus fragrance on immune function and depressive states</article-title><source>Neuroimmunomodulation</source><year>1995</year><volume>2</volume><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1159/000096889</pub-id><?supplied-pmid 8646568?><pub-id pub-id-type="pmid">8646568</pub-id></element-citation></ref><ref id="B33-molecules-22-01290"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Han</surname><given-names>T.</given-names></name><name><surname>Peng</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>X.R.</given-names></name></person-group><article-title>Antidepressant-like effects of essential oil and asarone, a major essential oil component from the rhizome of <italic>Acorus tatarinowii</italic></article-title><source>Pharm. Biol.</source><year>2013</year><volume>51</volume><fpage>589</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.3109/13880209.2012.751616</pub-id><?supplied-pmid 23363070?><pub-id pub-id-type="pmid">23363070</pub-id></element-citation></ref><ref id="B34-molecules-22-01290"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.J.</given-names></name><name><surname>Lim</surname><given-names>E.J.</given-names></name><name><surname>Zhao</surname><given-names>R.J.</given-names></name><name><surname>Oh</surname><given-names>S.R.</given-names></name><name><surname>Jung</surname><given-names>J.W.</given-names></name><name><surname>Ahn</surname><given-names>E.M.</given-names></name><name><surname>Lee</surname><given-names>E.S.</given-names></name><name><surname>Koo</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>H.Y.</given-names></name><name><surname>Chang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effect of the fragrance inhalation of essential oil from <italic>Asarum heterotropoides</italic> on depression-like behaviors in mice</article-title><source>BMC Complement. Altern. Med.</source><year>2015</year><volume>15</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1186/s12906-015-0571-1</pub-id><?supplied-pmid 25881143?><pub-id pub-id-type="pmid">25881143</pub-id></element-citation></ref><ref id="B35-molecules-22-01290"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komori</surname><given-names>T.</given-names></name><name><surname>Fujiwara</surname><given-names>R.</given-names></name><name><surname>Tanida</surname><given-names>M.</given-names></name><name><surname>Nomura</surname><given-names>J.</given-names></name></person-group><article-title>Potential antidepressant effects of lemon odor in rats</article-title><source>Eur. Neuropsychopharmacol.</source><year>1995</year><volume>5</volume><fpage>477</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1016/0924-977X(95)80007-O</pub-id><pub-id pub-id-type="pmid">8998400</pub-id></element-citation></ref><ref id="B36-molecules-22-01290"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komiya</surname><given-names>M.</given-names></name><name><surname>Takeuchi</surname><given-names>T.</given-names></name><name><surname>Harada</surname><given-names>E.</given-names></name></person-group><article-title>Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and DA activities in mice</article-title><source>Behav. Brain Res.</source><year>2006</year><volume>172</volume><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2006.05.006</pub-id><?supplied-pmid 16780969?><pub-id pub-id-type="pmid">16780969</pub-id></element-citation></ref><ref id="B37-molecules-22-01290"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>C.L.M.</given-names></name><name><surname>S&#x000e1;</surname><given-names>C.G.</given-names></name><name><surname>de Almeida</surname><given-names>A.A.</given-names></name><name><surname>da Costa</surname><given-names>J.P.</given-names></name><name><surname>Marques</surname><given-names>T.H.</given-names></name><name><surname>Feitosa</surname><given-names>C.M.</given-names></name><name><surname>Saldanha</surname><given-names>G.B.</given-names></name><name><surname>de Freitas</surname><given-names>R.M.</given-names></name></person-group><article-title>Sedative, anxiolytic and antidepressant activities of <italic>Citrus limon</italic> (Burn) essential oil in mice</article-title><source>Die Pharm.</source><year>2011</year><volume>66</volume><fpage>623</fpage><lpage>627</lpage></element-citation></ref><ref id="B38-molecules-22-01290"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Victoria</surname><given-names>F.N.</given-names></name><name><surname>de Siqueira</surname><given-names>A.B.</given-names></name><name><surname>Savegnago</surname><given-names>L.</given-names></name><name><surname>Lenard&#x000e3;o</surname><given-names>E.J.</given-names></name></person-group><article-title>Involvement of serotoninergic and adrenergic systems on the antidepressant-like effect of <italic>E. uniflora</italic> L. leaves essential oil and further analysis of its antioxidant activity</article-title><source>Neurosci. Lett.</source><year>2013</year><volume>544</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2013.03.054</pub-id><?supplied-pmid 23583586?><pub-id pub-id-type="pmid">23583586</pub-id></element-citation></ref><ref id="B39-molecules-22-01290"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seol</surname><given-names>G.H.</given-names></name><name><surname>Shim</surname><given-names>H.S.</given-names></name><name><surname>Kim</surname><given-names>P.J.</given-names></name><name><surname>Moon</surname><given-names>H.K.</given-names></name><name><surname>Lee</surname><given-names>K.H.</given-names></name><name><surname>Shim</surname><given-names>I.</given-names></name><name><surname>Suh</surname><given-names>S.H.</given-names></name><name><surname>Min</surname><given-names>S.S.</given-names></name></person-group><article-title>Antidepressant-like effect of <italic>Salvia sclarea</italic> is explained by modulation of dopamine activities in rats</article-title><source>J. Ethnopharmacol.</source><year>2010</year><volume>130</volume><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.04.035</pub-id><?supplied-pmid 20441789?><pub-id pub-id-type="pmid">20441789</pub-id></element-citation></ref><ref id="B40-molecules-22-01290"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzm&#x000e1;n-Guti&#x000e9;rrez</surname><given-names>S.L.</given-names></name><name><surname>G&#x000f3;mez-Cansino</surname><given-names>R.</given-names></name><name><surname>Garc&#x000ed;a-Zebad&#x000fa;a</surname><given-names>J.C.</given-names></name><name><surname>Jim&#x000e9;nez-P&#x000e9;rez</surname><given-names>N.C.</given-names></name><name><surname>Reyes-Chilpa</surname><given-names>R.</given-names></name></person-group><article-title>Antidepressant activity of <italic>Litsea glaucescens</italic> essential oil: Identification of &#x003b2;-pinene and linalool as active principles</article-title><source>J. Ethnopharmacol.</source><year>2012</year><volume>143</volume><fpage>673</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.07.026</pub-id><?supplied-pmid 22867633?><pub-id pub-id-type="pmid">22867633</pub-id></element-citation></ref><ref id="B41-molecules-22-01290"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>W.C.</given-names></name><name><surname>Seo</surname><given-names>J.M.</given-names></name><name><surname>Lee</surname><given-names>C.I.</given-names></name><name><surname>Pyo</surname><given-names>H.B.</given-names></name><name><surname>Lee</surname><given-names>B.C.</given-names></name></person-group><article-title>Stimulative and sedative effects of essential oils upon inhalation in mice</article-title><source>Arch. Pharm. Res.</source><year>2005</year><volume>28</volume><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1007/BF02977341</pub-id><?supplied-pmid 16114490?><pub-id pub-id-type="pmid">16114490</pub-id></element-citation></ref><ref id="B42-molecules-22-01290"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W.W.</given-names></name><name><surname>Li</surname><given-names>R.P.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>S.Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Niu</surname><given-names>X.X.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Antidepressant-like effect of essential oil of <italic>Perilla frutescens</italic> in a chronic, unpredictable, mild stress-induced depression model mice</article-title><source>Chin. J. Nat. Med.</source><year>2014</year><volume>12</volume><fpage>753</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/S1875-5364(14)60115-1</pub-id><pub-id pub-id-type="pmid">25443368</pub-id></element-citation></ref><ref id="B43-molecules-22-01290"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>L.T.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Geng</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>B.B.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Tu</surname><given-names>J.Q.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Weng</surname><given-names>L.J.</given-names></name></person-group><article-title>Essential oil of <italic>Perilla frutescens</italic>-induced change in hippocampal expression of brain-derived neurotrophic factor in chronic unpredictable mild stress in mice</article-title><source>J. Ethnopharmacol.</source><year>2013</year><volume>147</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2013.03.015</pub-id><?supplied-pmid 23506995?><pub-id pub-id-type="pmid">23506995</pub-id></element-citation></ref><ref id="B44-molecules-22-01290"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>D.G.</given-names></name><name><surname>Cunha</surname><given-names>M.P.</given-names></name><name><surname>Neis</surname><given-names>V.B.</given-names></name><name><surname>Balen</surname><given-names>G.O.</given-names></name><name><surname>Colla</surname><given-names>A.</given-names></name><name><surname>Bettio</surname><given-names>L.E.B.</given-names></name><name><surname>Oliveira</surname><given-names>A.</given-names></name><name><surname>Pazini</surname><given-names>F.L.</given-names></name><name><surname>Dalmarco</surname><given-names>J.B.</given-names></name><name><surname>Simionatto</surname><given-names>E.L.</given-names></name><etal/></person-group><article-title>Antidepressant-like effects of fractions, essential oil, carnosol and betulinic acid isolated from <italic>Rosmarinus officinalis</italic> L.</article-title><source>Food Chem.</source><year>2013</year><volume>136</volume><fpage>999</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2012.09.028</pub-id><?supplied-pmid 23122155?><pub-id pub-id-type="pmid">23122155</pub-id></element-citation></ref><ref id="B45-molecules-22-01290"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viana</surname><given-names>C.C.S.</given-names></name><name><surname>Oliveira</surname><given-names>P.A.</given-names></name><name><surname>Brum</surname><given-names>L.F.S.</given-names></name><name><surname>Picada</surname><given-names>J.N.</given-names></name><name><surname>Pereira</surname><given-names>P.</given-names></name></person-group><article-title>Gamma-decanolactone effect on behavioral and genotoxic parameters</article-title><source>Life Sci.</source><year>2007</year><volume>80</volume><fpage>1014</fpage><lpage>1019</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2006.11.042</pub-id><?supplied-pmid 17208256?><pub-id pub-id-type="pmid">17208256</pub-id></element-citation></ref><ref id="B46-molecules-22-01290"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccinelli</surname><given-names>A.C.</given-names></name><name><surname>Santos</surname><given-names>J.A.</given-names></name><name><surname>Konkiewitz</surname><given-names>E.C.</given-names></name><name><surname>Oesterreich</surname><given-names>S.A.</given-names></name><name><surname>Formagio</surname><given-names>A.S.</given-names></name><name><surname>Croda</surname><given-names>J.</given-names></name><name><surname>Ziff</surname><given-names>E.B.</given-names></name><name><surname>Kassuya</surname><given-names>C.A.</given-names></name></person-group><article-title>Antihyperalgesic and antidepressive actions of (R)-(+)-limonene, &#x003b1;-phellandrene, and essential oil from <italic>Schinus terebinthifolius</italic> fruits in a neuropathic pain model</article-title><source>Nutr. Neurosci.</source><year>2015</year><volume>18</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1179/1476830514Y.0000000119</pub-id><?supplied-pmid 24661285?><pub-id pub-id-type="pmid">24661285</pub-id></element-citation></ref><ref id="B47-molecules-22-01290"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.B.</given-names></name><name><surname>Luo</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>X.L.</given-names></name><name><surname>Geng</surname><given-names>D.</given-names></name><name><surname>Li</surname><given-names>C.F.</given-names></name><name><surname>Chen</surname><given-names>S.M.</given-names></name><name><surname>Chen</surname><given-names>X.M.</given-names></name><name><surname>Yi</surname><given-names>L.T.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name></person-group><article-title>Essential oil of <italic>Syzygium aromaticum</italic> reverses the deficits of stress-induced behaviors and hippocampal p-ERK/p-CREB/brain-derived neurotrophic factor expression</article-title><source>Planta Med.</source><year>2015</year><volume>81</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1396150</pub-id><?supplied-pmid 25590367?><pub-id pub-id-type="pmid">25590367</pub-id></element-citation></ref><ref id="B48-molecules-22-01290"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Tu</surname><given-names>Y.</given-names></name><name><surname>Jiao</surname><given-names>S.</given-names></name></person-group><article-title>Antidepressant-like effect of essential oil isolated from <italic>Toona ciliata</italic> Roem. var. <italic>yunnanensis</italic></article-title><source>J. Nat. Med.</source><year>2015</year><volume>69</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/s11418-014-0878-0</pub-id><?supplied-pmid 25465853?><pub-id pub-id-type="pmid">25465853</pub-id></element-citation></ref><ref id="B49-molecules-22-01290"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sah</surname><given-names>S.P.</given-names></name><name><surname>Mathela</surname><given-names>C.S.</given-names></name><name><surname>Chopra</surname><given-names>K.</given-names></name></person-group><article-title>Involvement of nitric oxide (NO) signalling pathway in the antidepressant activity of essential oil of <italic>Valeriana wallichii</italic> Patchouli alcohol chemotype</article-title><source>Phytomedicine</source><year>2011</year><volume>18</volume><fpage>1269</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2011.06.009</pub-id><?supplied-pmid 21795033?><pub-id pub-id-type="pmid">21795033</pub-id></element-citation></ref><ref id="B50-molecules-22-01290"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Norte</surname><given-names>M.C.</given-names></name><name><surname>Cosentino</surname><given-names>R.M.</given-names></name><name><surname>Lazarini</surname><given-names>C.A.</given-names></name></person-group><article-title>Effects of methyl-eugenol administration on behavioral models related to depression and anxiety, in rats</article-title><source>Phytomedicine</source><year>2005</year><volume>12</volume><fpage>294</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.phymed.2003.12.007</pub-id><?supplied-pmid 15898707?><pub-id pub-id-type="pmid">15898707</pub-id></element-citation></ref><ref id="B51-molecules-22-01290"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>R.P.</given-names></name><name><surname>Rivalan</surname><given-names>M.</given-names></name><name><surname>Bangasser</surname><given-names>D.A.</given-names></name><name><surname>Deussing</surname><given-names>J.M.</given-names></name><name><surname>Ising</surname><given-names>M.</given-names></name><name><surname>Wood</surname><given-names>S.K.</given-names></name><name><surname>Holsboer</surname><given-names>F.</given-names></name><name><surname>Summers</surname><given-names>C.H.</given-names></name></person-group><article-title>Evidence for the role of corticotropin-releasing factor in major depressive disorder</article-title><source>Neurosci. Biobehav. Rev.</source><year>2015</year><volume>58</volume><fpage>63</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2015.07.011</pub-id><?supplied-pmid 26271720?><pub-id pub-id-type="pmid">26271720</pub-id></element-citation></ref><ref id="B52-molecules-22-01290"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahi</surname><given-names>A.</given-names></name><name><surname>Al Mansouri</surname><given-names>S.</given-names></name><name><surname>Al Memari</surname><given-names>E.</given-names></name><name><surname>Al Ameri</surname><given-names>M.</given-names></name><name><surname>Nurulain</surname><given-names>S.M.</given-names></name><name><surname>Ojha</surname><given-names>S.</given-names></name></person-group><article-title>&#x003b2;-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice</article-title><source>Physiol. Behav.</source><year>2014</year><volume>135</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2014.06.003</pub-id><?supplied-pmid 24930711?><pub-id pub-id-type="pmid">24930711</pub-id></element-citation></ref><ref id="B53-molecules-22-01290"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gertsch</surname><given-names>J.</given-names></name><name><surname>Leonti</surname><given-names>M.</given-names></name><name><surname>Raduner</surname><given-names>S.</given-names></name><name><surname>Racz</surname><given-names>I.</given-names></name><name><surname>Chen</surname><given-names>J.Z.</given-names></name><name><surname>Xie</surname><given-names>X.Q.</given-names></name><name><surname>Altmann</surname><given-names>K.H.</given-names></name><name><surname>Karsak</surname><given-names>M.</given-names></name><name><surname>Zimmer</surname><given-names>A.</given-names></name></person-group><article-title>Beta-caryophyllene is a dietary cannabinoid</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>9099</fpage><lpage>9104</lpage><pub-id pub-id-type="doi">10.1073/pnas.0803601105</pub-id><?supplied-pmid 18574142?><pub-id pub-id-type="pmid">18574142</pub-id></element-citation></ref><ref id="B54-molecules-22-01290"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marco</surname><given-names>E.M.</given-names></name><name><surname>Garc&#x000ed;a-Guti&#x000e9;rrez</surname><given-names>M.S.</given-names></name><name><surname>Berm&#x000fa;dez-Silva</surname><given-names>F.J.</given-names></name><name><surname>Moreira</surname><given-names>F.A.</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>F.</given-names></name><name><surname>Manzanares</surname><given-names>J.</given-names></name><name><surname>Viveros</surname><given-names>M.P.</given-names></name></person-group><article-title>Endocannabinoid system and psychiatry: In search of a neurobiological basis for detrimental and potential therapeutic effects</article-title><source>Front. Behav. Neurosci.</source><year>2011</year><volume>5</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.3389/fnbeh.2011.00063</pub-id><?supplied-pmid 22007164?><pub-id pub-id-type="pmid">22007164</pub-id></element-citation></ref><ref id="B55-molecules-22-01290"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>A.</given-names></name><name><surname>Derecki</surname><given-names>N.C.</given-names></name><name><surname>Lovenberg</surname><given-names>T.W.</given-names></name><name><surname>Drevets</surname><given-names>W.C.</given-names></name></person-group><article-title>Role of neuro-immunological factors in the pathophysiology of mood disorders</article-title><source>Psychopharmacology</source><year>2016</year><volume>233</volume><fpage>1623</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1007/s00213-016-4214-0</pub-id><?supplied-pmid 26803500?><pub-id pub-id-type="pmid">26803500</pub-id></element-citation></ref><ref id="B56-molecules-22-01290"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>Y.Z.</given-names></name></person-group><article-title>Analysis of the volatile oil of <italic>Perilla frutescens</italic> drawing with two kinds of method by GC/MS</article-title><source>Chin. Condiment</source><year>2005</year><volume>30</volume><fpage>18</fpage><lpage>30</lpage></element-citation></ref><ref id="B57-molecules-22-01290"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>N.</given-names></name><name><surname>Nagai</surname><given-names>T.</given-names></name><name><surname>Oikawa</surname><given-names>T.</given-names></name><name><surname>Yamada</surname><given-names>H.</given-names></name><name><surname>Hanawa</surname><given-names>T.</given-names></name></person-group><article-title>Antidepressant-like effect of l-perillaldehyde in stress-induced depression-like model mice through regulation of the olfactory nervous system</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2011</year><volume>2011</volume><fpage>512697</fpage><pub-id pub-id-type="doi">10.1093/ecam/nen045</pub-id><?supplied-pmid 18955354?><pub-id pub-id-type="pmid">18955354</pub-id></element-citation></ref><ref id="B58-molecules-22-01290"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzm&#x000e1;n-Guti&#x000e9;rrez</surname><given-names>S.L.</given-names></name><name><surname>Bonilla-Jaime</surname><given-names>H.</given-names></name><name><surname>G&#x000f3;mez-Cansino</surname><given-names>R.</given-names></name><name><surname>Reyes-Chilpa</surname><given-names>R.</given-names></name></person-group><article-title>Linalool and &#x003b2;-pinene exert their antidepressant-like activity through the monoaminergic pathway</article-title><source>Life Sci.</source><year>2015</year><volume>128</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2015.02.021</pub-id><?supplied-pmid 25771248?><pub-id pub-id-type="pmid">25771248</pub-id></element-citation></ref><ref id="B59-molecules-22-01290"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coelho</surname><given-names>V.</given-names></name><name><surname>Mazzardo-Martins</surname><given-names>L.</given-names></name><name><surname>Martins</surname><given-names>D.F.</given-names></name><name><surname>Santos</surname><given-names>A.R.</given-names></name><name><surname>da Silva Brum</surname><given-names>L.F.</given-names></name><name><surname>Picada</surname><given-names>J.N.</given-names></name><name><surname>Pereira</surname><given-names>P.</given-names></name></person-group><article-title>Neurobehavioral and genotoxic evaluation of (-)-linalool in mice</article-title><source>J. Nat. Med.</source><year>2013</year><volume>67</volume><fpage>876</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1007/s11418-013-0751-6</pub-id><?supplied-pmid 23436179?><pub-id pub-id-type="pmid">23436179</pub-id></element-citation></ref><ref id="B60-molecules-22-01290"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>X.Y.</given-names></name><name><surname>Xue</surname><given-names>J.S.</given-names></name><name><surname>Li</surname><given-names>H.Y.</given-names></name><name><surname>Ma</surname><given-names>Z.Q.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Qu</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>S.P.</given-names></name></person-group><article-title>Geraniol produces antidepressant-like effects in a chronic unpredictable mild stress mice model</article-title><source>Physiol. Behav.</source><year>2015</year><volume>152</volume><fpage>264</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2015.10.008</pub-id><?supplied-pmid 26454213?><pub-id pub-id-type="pmid">26454213</pub-id></element-citation></ref><ref id="B61-molecules-22-01290"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irie</surname><given-names>Y.</given-names></name><name><surname>Itokazu</surname><given-names>N.</given-names></name><name><surname>Anjiki</surname><given-names>N.</given-names></name><name><surname>Ishige</surname><given-names>A.</given-names></name><name><surname>Watanabe</surname><given-names>K.</given-names></name><name><surname>Keung</surname><given-names>W.M.</given-names></name></person-group><article-title>Eugenol exhibits antidepressant-like activity in mice and induces expression of metallothionein- III in the hippocampus</article-title><source>Brain Res.</source><year>2004</year><volume>1011</volume><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2004.03.040</pub-id><?supplied-pmid 15157811?><pub-id pub-id-type="pmid">15157811</pub-id></element-citation></ref><ref id="B62-molecules-22-01290"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>G.</given-names></name><name><surname>Irie</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>D.J.</given-names></name><name><surname>Keung</surname><given-names>W.M.</given-names></name></person-group><article-title>Eugenol and its structural analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity</article-title><source>Bioorg. Med. Chem.</source><year>2005</year><volume>13</volume><fpage>4777</fpage><lpage>4788</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2005.04.081</pub-id><?supplied-pmid 15936201?><pub-id pub-id-type="pmid">15936201</pub-id></element-citation></ref><ref id="B63-molecules-22-01290"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brocardo</surname><given-names>P.S.</given-names></name><name><surname>Budni</surname><given-names>J.</given-names></name><name><surname>Lobato</surname><given-names>K.R.</given-names></name><name><surname>Kaster</surname><given-names>M.P.</given-names></name><name><surname>Rodrigues</surname><given-names>A.L.</given-names></name></person-group><article-title>Antidepressant-like effect of folic acid: Involvement of NMDA receptors andl-arginine&#x02013;nitric oxide&#x02013;cyclic guanosine monophosphate pathway</article-title><source>Eur. J. Pharmacol.</source><year>2008</year><volume>598</volume><fpage>37</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2008.08.033</pub-id><?supplied-pmid 18789921?><pub-id pub-id-type="pmid">18789921</pub-id></element-citation></ref><ref id="B64-molecules-22-01290"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jesse</surname><given-names>C.R.</given-names></name><name><surname>Bortolatto</surname><given-names>C.F.</given-names></name><name><surname>Savegnago</surname><given-names>L.</given-names></name><name><surname>Rocha</surname><given-names>J.B.</given-names></name><name><surname>Nogueira</surname><given-names>C.W.</given-names></name></person-group><article-title>Involvement of l-arginine&#x02013;nitric oxide&#x02013;cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2008</year><volume>32</volume><fpage>1838</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2008.08.010</pub-id><?supplied-pmid 18773934?><pub-id pub-id-type="pmid">18773934</pub-id></element-citation></ref><ref id="B65-molecules-22-01290"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crespi</surname><given-names>F.</given-names></name></person-group><article-title>The selective serotonin reuptake inhibitor fluoxetine reduces striatal in vivo levels of voltammetric nitric oxide (NO): A feature of its antidepressant activity?</article-title><source>Neurosci. Lett.</source><year>2010</year><volume>470</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2009.12.049</pub-id><?supplied-pmid 20036714?><pub-id pub-id-type="pmid">20036714</pub-id></element-citation></ref><ref id="B66-molecules-22-01290"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhir</surname><given-names>A.</given-names></name><name><surname>Kulkarni</surname><given-names>S.K.</given-names></name></person-group><article-title>Involvement of l-arginine&#x02013;nitric oxide&#x02013;cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice</article-title><source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><year>2007</year><volume>31</volume><fpage>921</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1016/j.pnpbp.2007.02.008</pub-id><?supplied-pmid 17379375?><pub-id pub-id-type="pmid">17379375</pub-id></element-citation></ref><ref id="B67-molecules-22-01290"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghasemi</surname><given-names>M.</given-names></name><name><surname>Montaser-Kouhsari</surname><given-names>L.</given-names></name><name><surname>Shafaroodi</surname><given-names>H.</given-names></name><name><surname>Nezami</surname><given-names>B.G.</given-names></name><name><surname>Ebrahimi</surname><given-names>F.</given-names></name><name><surname>Dehpour</surname><given-names>A.R.</given-names></name></person-group><article-title>NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test</article-title><source>Psychopharmacology</source><year>2009</year><volume>206</volume><fpage>325</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1007/s00213-009-1609-1</pub-id><?supplied-pmid 19609507?><pub-id pub-id-type="pmid">19609507</pub-id></element-citation></ref><ref id="B68-molecules-22-01290"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melo</surname><given-names>F.H.</given-names></name><name><surname>Moura</surname><given-names>B.A.</given-names></name><name><surname>de Sousa</surname><given-names>D.P.</given-names></name><name><surname>de Vasconcelos</surname><given-names>S.M.</given-names></name><name><surname>Macedo</surname><given-names>D.S.</given-names></name><name><surname>Fonteles</surname><given-names>M.M.</given-names></name><name><surname>Viana</surname><given-names>G.S.</given-names></name><name><surname>de Sousa</surname><given-names>F.C.</given-names></name></person-group><article-title>Antidepressant-like effect of carvacrol (5-Isopropyl-2-methylphenol) in mice: Involvement of dopaminergic system</article-title><source>Fundam. Clin. Pharmacol.</source><year>2011</year><volume>25</volume><fpage>362</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1111/j.1472-8206.2010.00850.x</pub-id><?supplied-pmid 20608992?><pub-id pub-id-type="pmid">20608992</pub-id></element-citation></ref><ref id="B69-molecules-22-01290"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>H.Y.</given-names></name><name><surname>Yang</surname><given-names>Y.X.</given-names></name><name><surname>Guo</surname><given-names>J.Y.</given-names></name></person-group><article-title>Cinnamic aldehyde treatment alleviates chronic unexpected stress-induced depressive-like behaviors via targeting cyclooxygenase-2 in mid-aged rats</article-title><source>J. Ethnopharmacol.</source><year>2015</year><volume>162</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2014.12.047</pub-id><?supplied-pmid 25556926?><pub-id pub-id-type="pmid">25556926</pub-id></element-citation></ref><ref id="B70-molecules-22-01290"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W.W.</given-names></name><name><surname>Wang</surname><given-names>S.Y.</given-names></name><name><surname>Ma</surname><given-names>Z.Q.</given-names></name><name><surname>Li</surname><given-names>R.P.</given-names></name><name><surname>Li</surname><given-names>S.S.</given-names></name><name><surname>Xue</surname><given-names>J.S.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Niu</surname><given-names>X.X.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Effects of perillaldehyde on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration</article-title><source>Pharmacol. Biochem. Behav.</source><year>2014</year><volume>116</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2013.10.026</pub-id><?supplied-pmid 24201050?><pub-id pub-id-type="pmid">24201050</pub-id></element-citation></ref><ref id="B71-molecules-22-01290"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>M.I.G.</given-names></name><name><surname>Aquino Neto</surname><given-names>M.R.</given-names></name><name><surname>Neto</surname><given-names>P.F.T.</given-names></name><name><surname>Moura</surname><given-names>B.A.</given-names></name><name><surname>do Amaral</surname><given-names>J.F.</given-names></name><name><surname>de Sousa</surname><given-names>D.P.</given-names></name><name><surname>Vasconcelos</surname><given-names>S.M.M.</given-names></name><name><surname>de Sousa</surname><given-names>F.C.F.</given-names></name></person-group><article-title>Central nervous system activity of acute administration of isopulegol in mice</article-title><source>Pharmacol. Biochem. Behav.</source><year>2007</year><volume>88</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2007.07.015</pub-id><?supplied-pmid 17716715?><pub-id pub-id-type="pmid">17716715</pub-id></element-citation></ref><ref id="B72-molecules-22-01290"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Deng</surname><given-names>X.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name></person-group><article-title><sc>l</sc>-Menthone confers antidepressant-like effects in an unpredictable chronic mild stress mouse model via NLRP3 inflammasome-mediated inflammatory cytokines and central neurotransmitters</article-title><source>Pharmacol. Biochem. Behav.</source><year>2015</year><volume>134</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2015.04.014</pub-id><?supplied-pmid 25937574?><pub-id pub-id-type="pmid">25937574</pub-id></element-citation></ref><ref id="B73-molecules-22-01290"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>X.Y.</given-names></name><name><surname>Li</surname><given-names>H.Y.</given-names></name><name><surname>Chen</surname><given-names>J.J.</given-names></name><name><surname>Li</surname><given-names>R.P.</given-names></name><name><surname>Qu</surname><given-names>R.</given-names></name><name><surname>Fu</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>S.P.</given-names></name></person-group><article-title>Thymol produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in mice</article-title><source>Behav. Brain Res.</source><year>2015</year><volume>291</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2015.04.052</pub-id><?supplied-pmid 25958231?><pub-id pub-id-type="pmid">25958231</pub-id></element-citation></ref><ref id="B74-molecules-22-01290"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aquib</surname><given-names>M.</given-names></name><name><surname>Najmi</surname><given-names>A.K.</given-names></name><name><surname>Akhtar</surname><given-names>M.</given-names></name></person-group><article-title>Antidepressant effect of thymoquinone in animal models of depression</article-title><source>Drug Res.</source><year>2015</year><volume>65</volume><fpage>490</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1055/s-0034-1389920</pub-id><?supplied-pmid 25207705?><pub-id pub-id-type="pmid">25207705</pub-id></element-citation></ref><ref id="B75-molecules-22-01290"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoeb</surname><given-names>A.</given-names></name><name><surname>Chowta</surname><given-names>M.</given-names></name><name><surname>Pallempati</surname><given-names>G.</given-names></name><name><surname>Rai</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name></person-group><article-title>Evaluation of antidepressant activity of vanillin in mice</article-title><source>Indian J. Pharmacol.</source><year>2013</year><volume>45</volume><fpage>141</fpage><lpage>144</lpage><?supplied-pmid 23716889?><pub-id pub-id-type="pmid">23716889</pub-id></element-citation></ref><ref id="B76-molecules-22-01290"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakusi&#x00107;</surname><given-names>B.</given-names></name><name><surname>Lakusi&#x00107;</surname><given-names>D.</given-names></name><name><surname>Risti&#x00107;</surname><given-names>M.</given-names></name><name><surname>Marceti&#x00107;</surname><given-names>M.</given-names></name><name><surname>Slavkovska</surname><given-names>V.</given-names></name></person-group><article-title>Seasonal variations in the composition of the essential oils of <italic>Lavandula angustifolia</italic> (Lamiacae)</article-title><source>Nat. Prod. Commun.</source><year>2014</year><volume>9</volume><fpage>859</fpage><lpage>862</lpage><?supplied-pmid 25115100?><pub-id pub-id-type="pmid">25115100</pub-id></element-citation></ref><ref id="B77-molecules-22-01290"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.S.</given-names></name><name><surname>Adibfar</surname><given-names>A.</given-names></name><name><surname>Herrmann</surname><given-names>N.</given-names></name><name><surname>Gallagher</surname><given-names>D.</given-names></name><name><surname>Lanct&#x000f4;t</surname><given-names>K.L.</given-names></name></person-group><article-title>Evidence for inflammation-associated depression</article-title><source>Curr. Top. Behav. Neurosci.</source><year>2017</year><volume>31</volume><fpage>3</fpage><lpage>30</lpage><?supplied-pmid 27221622?><pub-id pub-id-type="pmid">27221622</pub-id></element-citation></ref><ref id="B78-molecules-22-01290"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Moura</surname><given-names>J.C.</given-names></name><name><surname>Noroes</surname><given-names>M.M.</given-names></name><name><surname>Rachetti</surname><given-names>V.P.S.</given-names></name><name><surname>Soares</surname><given-names>B.L.</given-names></name><name><surname>Delia</surname><given-names>P.</given-names></name><name><surname>Nassini</surname><given-names>R.</given-names></name><name><surname>Materazzi</surname><given-names>S.</given-names></name><name><surname>Marone</surname><given-names>I.M.</given-names></name><name><surname>Minocci</surname><given-names>D.</given-names></name><name><surname>Geppetti</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The blockade of transient receptor potential ankirin 1 (TRPA1) signalling mediates antidepressant- and anxiolytic-like actions in mice</article-title><source>Br. J. Pharmacol.</source><year>2014</year><volume>171</volume><fpage>4289</fpage><lpage>4299</lpage><pub-id pub-id-type="doi">10.1111/bph.12786</pub-id><?supplied-pmid 24846744?><pub-id pub-id-type="pmid">24846744</pub-id></element-citation></ref><ref id="B79-molecules-22-01290"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riella</surname><given-names>K.R.</given-names></name><name><surname>Marinho</surname><given-names>R.R.</given-names></name><name><surname>Santos</surname><given-names>J.S.</given-names></name><name><surname>Pereira-Filho</surname><given-names>R.N.</given-names></name><name><surname>Cardoso</surname><given-names>J.C.</given-names></name><name><surname>Albuquerque-Junior</surname><given-names>R.L.</given-names></name><name><surname>Thomazzi</surname><given-names>S.M.</given-names></name></person-group><article-title>Anti-inflammatory and cicatrizing activities of thymol, a monoterpene of the essential oil from <italic>Lippia gracilis</italic>, in rodents</article-title><source>J. Ethnopharmacol.</source><year>2012</year><volume>143</volume><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2012.07.028</pub-id><?supplied-pmid 22885071?><pub-id pub-id-type="pmid">22885071</pub-id></element-citation></ref><ref id="B80-molecules-22-01290"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>S.K.</given-names></name><name><surname>Sultana</surname><given-names>S.</given-names></name></person-group><article-title>Geraniol attenuates 2-acetylaminofluorene induced oxidative stress, inflammation and apoptosis in the liver of wistar rats</article-title><source>Toxicol. Mech. Methods</source><year>2015</year><volume>25</volume><fpage>559</fpage><lpage>573</lpage><?supplied-pmid 26364502?><pub-id pub-id-type="pmid">26364502</pub-id></element-citation></ref><ref id="B81-molecules-22-01290"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koivisto</surname><given-names>A.</given-names></name><name><surname>Chapman</surname><given-names>H.</given-names></name><name><surname>Jalava</surname><given-names>N.</given-names></name><name><surname>Korjamo</surname><given-names>T.</given-names></name><name><surname>Saarnilehto</surname><given-names>M.</given-names></name><name><surname>Lindstedt</surname><given-names>K.</given-names></name><name><surname>Pertovaara</surname><given-names>A.</given-names></name></person-group><article-title>TRPA1: A transducer and amplifier of pain and inflammation</article-title><source>Basic Clin. Pharmacol. Toxicol.</source><year>2014</year><volume>114</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/bcpt.12138</pub-id><?supplied-pmid 24102997?><pub-id pub-id-type="pmid">24102997</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="molecules-22-01290-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-22-01290-t001_Table 1</object-id><label>Table 1</label><caption><p>Aromatic plant essential oils studied in experimental depression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Essential Oils</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Administration via and Duration of Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Animal Specie</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose Range Tested and Minimal Active Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Behavioral Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observed Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Acorus tatarinowii</italic> Schott</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">30&#x02013;240 mg/kg <break/>(60 mg/kg)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in both assays</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B33-molecules-22-01290" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U-inverted curve</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Asarum heterotropoides</italic> F. Schmidt</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.25&#x02013;2.0 g <break/>(0.25 g)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in both tests</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reversed the increase of CRF- and TH-positive cells in the paraventricular nucleus, and locus coeruleus, respectively;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DR+<break/>Controls: negative and positive (fluoxetine)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B34-molecules-22-01290" ref-type="bibr">34</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reversed the decrease of 5-HT-positive cells in the dorsal raphe nucleus</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Citrus limon</italic> (L.) Osbeck</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Saturated chamber <break/>(90 min)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The treatment with flumazenil (GABA<sub>A</sub> antagonist), buspirone (5-HT<sub>1A</sub> partial agonist), DOI (5-HT<sub>2A</sub> receptor agonist), miaserin (5-HT<sub>2A/C</sub> receptor agonist), apomorphin (D receptor agonist) and haloperidol (D receptor antagonist) blocked the antidepressant effect. Increased hippocampal DA and prefrontal cortex and hippocampal 5-HT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B35-molecules-22-01290" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine and imipramine)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced spontaneous locomotor activity</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Citrus limon</italic> (L.) Osbeck</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rats</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Saturated chamber <break/>(60 min)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B36-molecules-22-01290" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced spontaneous locomotor activity</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Citrus limon</italic> (L.) Osbeck</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 30 days</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">50&#x02013;150 mg/kg <break/>(50 mg/kg)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B37-molecules-22-01290" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine and paroxetine)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment decreased spontaneous locomotion increased sleeping duration</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Eugenia uniflora</italic> L.</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1&#x02013;50 mg/kg <break/>(10 mg/kg)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The blockade of 5-HT2<sub>A/C</sub>, &#x003b1;<sub>1</sub> and &#x003b1;<sub>2</sub>-receptors prevented the antidepressant effects;</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DR+<break/>Controls: negative and positive (fluoxetine)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B38-molecules-22-01290" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In vitro inhibition of linoleic acid peroxidation;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced SNP-induced lipoperoxidation in cortex, hippocampus and cerebellum</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Lavandula angustif&#x000f3;lia</italic> Mill.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rat</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5&#x02013;20% (5%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B39-molecules-22-01290" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine and imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Lavandula angustif&#x000f3;lia</italic> Mill.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Saturated chamber <break/>(90 min)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">No effects were observed</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B35-molecules-22-01290" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine and imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Litsea glaucescens</italic> Kunth</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">54.8&#x02013;300 mg/kg <break/>(100 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Mentha</italic> &#x000d7; <italic>piperita</italic> L.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse (female)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Saturated chamber <break/>(10 min)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B41-molecules-22-01290" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Perilla frutescens</italic> L. Britton</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 3 weeks</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3&#x02013;9 mg/kg <break/>(3 mg/kg)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS, FST, TST, OFT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Restored sucrose preference in CUMS mice;</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed the 5-HT and 5-HIAA reduced concentrations in CUMS mice; <break/>Restored the serum IL-6, IL-1&#x003b2;, and TNF-&#x003b1; levels in CUMS mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B42-molecules-22-01290" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reverted the reduced spontaneous locomotion in CUMS mice;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U-inverted curve</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Restored increased immobility time in CUMS mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Perilla frutescens</italic> L. Britton</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 3 and 4 weeks</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3&#x02013;6 mg/kg <break/>(3 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS, FST, sucrose preference</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored the CUMS-induced decreased sucrose preference and increased immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored the CUMS-induced reduction of hippocampal protein and mRNA BDNF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B43-molecules-22-01290" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Rosmarinus officinalis</italic> L.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1&#x02013;100 mg/kg <break/>(0.1 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B44-molecules-22-01290" ref-type="bibr">44</xref>,<xref rid="B45-molecules-22-01290" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Rosmarinus officinalis</italic> L.</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rat</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5&#x02013;20% <break/>(5%)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B39-molecules-22-01290" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U-inverted curve</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine and imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Salvia sclarea</italic> L.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal and inhalation, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rat</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5&#x02013;20% (5%); satured chamber <break/>(1, 2, 4 and 6 h)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time when injected and inhaled</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The pretreatment with haloperidol (Dopamine receptor antagonist), SCH-23390 (D1 receptor antagonist) and buspirone (5-HT<sub>1A</sub> partial agonist) blocked the antidepressant effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B39-molecules-22-01290" ref-type="bibr">39</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine and imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Schinus terebinthifolius</italic> Raddi</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 15 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wistar rats</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored increased immobility time in rats subjected to a model of neuropathic pain</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B46-molecules-22-01290" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (ketamine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Syzygium aromaticum</italic> (L.) Merr, &#x00026; L.M.Perry</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">50&#x02013;200 mg/kg <break/>(100 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in both tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B47-molecules-22-01290" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine) LD<sub>50</sub> = 45564.556 g/kg (po)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Syzygium aromaticum</italic> (L.) Merr, &#x00026; L.M.Perry</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 5 weeks</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rat</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">50&#x02013;200 mg/kg <break/>(50 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS, novelty-suppressed feeding behavior</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored sucrose preference in CUMS rats; <break/>Reverted the increased latency to feed in a unfamiliar environment in CUMS rats</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored hippocampal BDNF protein, p-ERK and p-CREB expression</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B47-molecules-22-01290" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Thymus vulgaris</italic> L. (Lamiaceae)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse (female)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Saturated chamber <break/>(10 min)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B41-molecules-22-01290" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Toona ciliata</italic> Roem. var. <italic>yunnanensis</italic> (C. DC.) C.Y. WU</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10&#x02013;80 mg/kg <break/>(10 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in both tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B48-molecules-22-01290" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Toona ciliata Roem</italic> var. yunnanensis (C. DC.) C.Y. WU</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rat</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10&#x02013;80 mg/kg <break/>(10 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">No behavioral effects were evaluated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased hippocampal monoamines (5-HT, NE and DA) and BDNF contents in CUMS rats;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DR+<break/>Controls: negative and positive (imipramine)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B48-molecules-22-01290" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced serum corticosterone in CUMS rats</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Valeriana wallichii</italic> DC.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute and 14 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Albino Laca mouse (male and female)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10&#x02013;40 mg/kg <break/>(10 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Increased noradrenaline and 5-HT levels after repeated administration; The acute antidepressant effect was prevented by pretreatment with L-arginine (NO precursor) and sildenafil (phosphodiesterase 5 inhibitor), while it was potentiated with L-NAME (NOS inhibitor) and methylene blue (inhibitor of soluble guanylate cyclase)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B49-molecules-22-01290" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><italic>Zingiber officinale</italic> Roscoe</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse (female)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Saturated chamber <break/>(10 min)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B41-molecules-22-01290" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative</td></tr></tbody></table><table-wrap-foot><fn><p>FST: forced swimming test; TST: tail suspension test; OFT: open field test; CUMS: Chronic unpredictable mild stress; DR&#x02212;: absence of dose/concentration response; DR+: dose/concentration response design; 5-HT: serotonin; DA: dopamine; NE: noradrenaline.</p></fn></table-wrap-foot></table-wrap><table-wrap id="molecules-22-01290-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-22-01290-t002_Table 2</object-id><label>Table 2</label><caption><p>Constituents from essential oils tested in experimental depression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Constituents</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Via of Administration and Duration of Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Animal Specie</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose Range Tested and Minimal Active Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Behavioral Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observed Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanism of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i001.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">5&#x02013;20 mg/kg (10 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in both assays</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B33-molecules-22-01290" ref-type="bibr">33</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asarone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i002.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">C57BL/6 mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">50 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST, novelty-suppressed feeding behavior</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in the TST and the FST; decreased feeding latency in the novelty-suppressed feeding test</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The pretreatment with AM630 (CB<sub>2</sub> antagonist) prevented the anti-immobility effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-molecules-22-01290" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;-Caryophyllene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i003.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12.5&#x02013;50 mg/kg (12.5 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in both tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The pretreatment with SCH23390 (D<sub>1</sub> antagonist) and sulpiride (D<sub>2</sub> antagonist) prevented the anti-immobility effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-molecules-22-01290" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carvacrol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i004.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 21 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rat, 18 months old</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">22.5&#x02013;90 mg/kg (45 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed decreased sucrose preference and spontaneous locomotion in CUMS rats</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed the increased hippocampal COX-2 protein and activity; Reversed the elevated PGE<sub>2</sub> concentration in frontal cortex and hippocampus in CUMS rats</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-molecules-22-01290" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cinnamic aldehyde</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i005.jpg"/></td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, acute</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SD rats</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Saturated chamber (60 min)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-molecules-22-01290" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Citral</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hypolocomotion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i006.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wistar rat</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1&#x02013;0.3 g/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">No effects</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-molecules-22-01290" ref-type="bibr">45</xref>,<xref rid="B70-molecules-22-01290" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;-Decanolactone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative Hypolocomotion at higher doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i007.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">No effects</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eucalyptol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i008.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, 14 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ddY mice</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10&#x02013;100 mg/kg (30 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in the TST and increased number of wheel rotations in the FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Increased Hippocampal BDNF and metallothionein-III (brain-predominant protein that alleviates various neurotoxic events) mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-molecules-22-01290" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Eugenol</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral, mixed with drinking water, 14 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.17 mmol/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Increased number of wheel rotations in the FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhibits human MAO<sub>A</sub> (IC50 34.4 &#x000b5;M) preferencially than MAO<sub>B</sub> (IC<sub>50</sub> 288 &#x000b5;M) activity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-molecules-22-01290" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i009.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 4 weeks</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">20&#x02013;40 mg/kg (20 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS, FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored decreased sucrose preference and increased immobility time in the TST and FST in mice subjected to CUMS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed the IL-1&#x003b2;-related CNS inflammation by markedly inhibiting CUMS-induced PFC NF-&#x003ba;B pathway and modulating NLRP3 inflammasome activation (activated caspase 1) in CUMS mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-molecules-22-01290" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geraniol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i010.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">25&#x02013;50 mg/kg (25 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Increased immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-molecules-22-01290" ref-type="bibr">71</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isopulegol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i011.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 15 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wistar rat</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored increased immobility time in rats subjected to a model of neuropathic pain</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-molecules-22-01290" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (ketamine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Limonene</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">No effects</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i012.jpg"/><break/>Linalool</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">54.8&#x02013;173.2 mg/kg (100 mg/kg)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">U-inverted curve</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment reduced spontaneous locomotion</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The pretreatment with WAY100,635 (5-HT<sub>1A</sub> antagonist) and yohimbine (&#x003b1;<sub>2</sub>-antagonist) prevented the antidepressant-like effects</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10&#x02013;200 mg/kg (100 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B59-molecules-22-01290" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i013.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 3 weeks</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15&#x02013;30 mg/kg (15 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS, FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed the decrease of sucrose consumption, the hypolocomotion and the increased immobile time in the TST and FST in CUMS mice</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored the CUMS-induced reductions in hippocampal NE and 5-HT levels; Reverted the increased hippocampal pro-inflammatory cytokines levels (IL-1&#x003b2;, IL-6, and TNF&#x003b1;) in CUMS mice;<break/>Inhibited the increased hippocampal nod-like receptor protein 3 (NLRP3) inflammasome, and caspase-1 protein expression in CUMS mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-molecules-22-01290" ref-type="bibr">72</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Menthone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i014.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wistar rats</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.0&#x02013;10.0 &#x000b5;l/mL/kg (1.0 &#x000b5;l/mL/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-molecules-22-01290" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methyl-eugenol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i015.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">No effects</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-Pinene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i016.jpg"/><break/>&#x003b2;-Pinene</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">54.8&#x02013;173.2 mg/kg (100 mg/kg)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B40-molecules-22-01290" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The treatment reduced the spontaneous locomotion</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, three times within 24 h</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">100 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The pretreatment with WAY100,635 (5-HT<sub>1A</sub> antagonist), propranolol (&#x003b2;-antagonist), DSP-4 (NE neurotoxin), SCH23390 (D<sub>1</sub> antagonist) prevented the anti-immobility effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B58-molecules-22-01290" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (imipramine)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i017.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 7 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">60&#x02013;120 mg/kg (60 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LPS-induced depressant-like behavior, FST and TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed increased in immobility time in the FST and TST in LPS-treated mice</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed the reduced concentrations of 5-HT and NE, and attenuated LPS-induced increases of serum protein levels and prefrontal cortex mRNA of TNF-&#x003b1; and IL-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-molecules-22-01290" ref-type="bibr">70</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Perillaldehyde</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Inhalation, 9 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ddY mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1&#x02013;10% dropped on the area between eyes and nose (1%)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS, FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in na&#x000ef;ve mouse and reversed increased immobility time in CUMS mice</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B57-molecules-22-01290" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (minalcipran)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i018.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, once daily, 15 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Wistar rat</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored increased immobility time in rats subjected to a model of neuropathic pain</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-molecules-22-01290" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-Phellandrene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (ketamine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i019.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, 3 weeks</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ICR mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">15&#x02013;30 mg/kg (15 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CUMS, TST, FST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reversed the decrease of sucrose consumption, the loss of body weight, and the increased immobile time in the TST and FST in CUMS mice</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Restored the CUMS-induced reductions in hippocampal NE and 5-HT; Reverted the increased hippocampal mRNA of pro-inflammatory cytokines (IL-1&#x003b2;, IL-6, and TNF&#x003b1;) in CUMS mice; Inhibited the activation of nod-like receptor protein 3 (NLRP3) inflammasome and its adaptor, and subsequently decreased the expression of caspase-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-molecules-22-01290" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thymol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i020.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Intraperitoneal, acute</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">20 mg/kg</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time in both tests</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">A significant elevation of 5-HT whole brain levels was observed; Increased glutathione levels and decreased TBARS levels in the whole brain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR&#x02212;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-molecules-22-01290" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thymoquinone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><inline-graphic xlink:href="molecules-22-01290-i021.jpg"/></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Oral gavage, acute and 10 days</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Swiss mouse (male and female)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">10&#x02013;100 mg/kg (10 mg/kg)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">FST, TST</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Reduced immobility time under acute and chronic treatments</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DR+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-molecules-22-01290" ref-type="bibr">75</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vanillin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Controls: negative and positive (fluoxetine and imipramine)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>FST: forced swimming test; TST: tail suspension test; OFT: open field test; CUMS: Chronic unpredictable mild stress; DR+: dose/concentration response design; DR&#x02212;-: absence of dose/concentration response; 5-HT: serotonin; DA: dopamine; NE: noradrenaline.</p></fn></table-wrap-foot></table-wrap></floats-group></article>